For a supplemental table listing contact information for organizations that can serve as a resource to persons with PD (as well as other movement disorders) and their families, go to http://thepoint.lww.com/AT10e.
Etiology
The etiology of PD is poorly understood. Most evidence suggests it is multifactorial, and attributable to a complex interplay between age-related changes in the nigrostriatal tract, underlying genetic risks, and environmental triggers. Support for this hypothesis can be found in several historic observations, most notably the postviral parkinsonian symptoms occurring after epidemics of encephalitis in the early 1900s, and the discovery that ingestion of a meperidine analog, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), by heroin addicts in northern California during the early 1980s caused a rapid and irreversible parkinsonism. 8 (For an excellent in-depth discussion of the importance of the MPTP discovery and its influence on PD research, please view the episode "My Father, My Brother, and Me" from the Public Broadcasting System program Frontline at http://www.pbs.org/wgbh/pages/frontline/parkinsons/).
The relative contributions of environment and genetics to the occurrence of PD remains controversial; rural living, pesticide exposure, and consumption of well water have consistently been associated with increased lifetime risk of PD, whereas cigarette smoking and caffeine ingestion appear protective. 9 Mutations in several genes, including α-synuclein (SNCA), leucine-rich repeat kinase-2 (LRRK2), parkin, PTEN-induced kinase-1 (PINK1), and DJ-1, have been observed in rare familial inherited cases of PD, but these genes lack typical Mendelian patterns of inheritance, and do not account for the threefold increased risk of developing PD for individuals who have a first-degree relative affected with sporadic PD. 10 Recent advances in molecular genetics and genome-wide association studies have revealed other novel risk genes; however, the exact linkage between genetics, environment, and clinical expression of disease remains uncertain.
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Pathophysiology PD affects the portion of the extrapyramidal system of the brain involving the basal ganglia, an area composed of the substantia nigra, neostriatum, and globus pallidus. Together, they are involved with maintaining posture and muscle tone and regulating voluntary smooth motor activity. The pigmented neurons within the substantia nigra have dopaminergic fibers that project into the neostriatum and globus pallidus, and in PD, these dopamine-producing neurons are progressively depigmented.
For an image of the areas of the brain affected by PD, go to http://thepoint.lww.com/ AT10e.
Postmortem pathologic examination of the basal ganglia reveals the presence of Lewy bodies within the remaining dopaminergic cells of the substantia nigra. 12 These abnormal intraneuronal protein aggregates are considered pathognomonic for the disease. Lewy body pathology appears to ascend the brain in a predictable manner in PD, beginning in the medulla oblongata in preclinical stages (which may explain observations of anxiety, depression, and olfactory disturbance), ascending to the midbrain (motor dysfunction), and spreading eventually to the cortex (cognitive and behavioral changes). 13 The exact pathological sequence leading to neurodegeneration is unclear, but free radicals formed as by-products of dopamine auto-oxidation have been implicated. The oxidative stress imparted by these events may provide the stimulus for inflammation and cellular apoptosis, thereby initiating the cascade of neurodegeneration. The finding that a critical threshold of neuronal loss (at least 70%-80%) occurs before PD becomes
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clinically apparent suggests that adaptive mechanisms (e.g., upregulation of dopamine synthesis or downregulation of synaptic dopamine reuptake) may somehow influence disease progression during the preclinical stages.
Overview of Drug Therapy
Because the salient pathophysiologic feature of PD is the progressive loss of dopamine from the nigrostriatal tracts in the brain, drug therapy for the disease is aimed primarily at replenishing the supply of dopamine (Table 57-1) . This is accomplished through one, or a combination, of the following methods: (a) administering exogenous dopamine in the form of a precursor, levodopa; (b) stimulating dopamine receptors within the corpus striatum through the use of dopamine agonists (e.g., pramipexole, ropinirole); or (c) inhibiting the major metabolic pathways within the brain that are responsible for the degradation of levodopa and its metabolites. This latter effect is achieved through the use of aromatic l-amino acid decarboxylase (AAD) inhibitors (e.g., carbidopa), catechol-O-methyltransferase (COMT) inhibitors (e.g., entacapone), or monoamine oxidase type B (MAO-B) inhibitors (e.g., selegiline, rasagiline). Additional therapies such as anticholinergics may be used to improve tremor thought to be attributable to the relative increase in cholinergic activity that occurs as a consequence of loss of dopamine-mediated inhibition of acetylcholine neurons. Their routine use, however, is limited by central nervous system adverse effects, particularly in older patients. Amantadine is also used occasionally, and may provide modest benefits via both dopaminergic and nondopaminergic (inhibition of glutamate) mechanisms.
Despite optimization of both pharmacologic and nonpharmacologic therapies in PD, physical disability is progressive and unavoidable. In many instances, adverse effects of the medications themselves can lead to additional problems. Supportive drug treatment of the associated comorbidities of PD is also necessary. These include neuropsychiatric problems (cognitive impairment and dementia, hallucinations and delirium, depression, agitation, anxiety), autonomic dysfunction (constipation, urinary problems, sexual problems, orthostasis, thermoregulatory imbalances), falls, and sleep disorders (insomnia or sleep fragmentation, nightmares, restless leg syndrome).
CLINICAL PRESENTATION OF PARKINSON DISEASE
CASE 57-1 QUESTION 1: L.M., a 55-year-old, right-handed male artist, presents to the neurology clinic complaining of difficulty painting because of unsteadiness in his right hand. On questioning, he notes that it is becoming increasingly difficult to get out of chairs after sitting for a long period because of tightness in his arms and legs. He also reports having a loss in sense of smell and has noticed excessive drooling, especially at night. His wife claims that he has become more "forgetful" lately, and L.M. admits that his memory does not seem to be as sharp as it once was. His medical history is significant for depression for the past year, gout (currently requiring no treatment), constipation, benign prostatic hypertrophy, and aortic stenosis. He does not smoke, but usually drinks one alcoholic beverage in the evenings. His only prescription medication is citalopram 10 mg/day. On physical examination, L.M. is noted to be a well-developed, well-nourished man who displays a notable lack of normal changes in facial expression and speaks in a soft, monotone voice. A strong body odor is noted. Examination of his extremities reveals a slight ratchetlike rigidity in both arms and legs, and a mild resting tremor is present in his right hand. His gait is slow but otherwise normal, with a slightly bent posture. His balance is determined to be normal, with no retropulsion or loss of righting reflexes after physical threat. His genitourinary examination is remarkable only for prostatic enlargement. The remainder of L.M.'s physical examination is within normal limits. Laboratory values and vital signs obtained at this visit include the following:
Blood pressure, 119/66 mm Hg Heart rate, 71 beats/minute Sodium, 132 mEq/L Potassium, 4.4 mEq/L Blood urea nitrogen, 19 mg/dL Creatinine, 1.1 mg/dL Thyroid stimulating hormone, 3.65 microunits/L Vitamin B 12 , 612 pg/mL Folate, 5.2 ng/mL White blood cells, 4,400 cells/μL Red blood cells, 5.9 × 10 6 /μL Hemoglobin, 13.8 g/dL Hematocrit, 41% Uric acid, 6.3 mg/dL How is PD diagnosed? What signs and symptoms suggestive of PD are present in L.M.? Which of these symptoms are among the classic symptoms for diagnosing PD, and which are considered associated symptoms? Is neuroimaging or any other testing helpful in establishing the diagnosis of PD?
The foundation for establishing the diagnosis of PD remains firmly grounded in obtaining a careful history and physical examination. 12 The neurologic examination to assess motor function, along with a positive response to levodopa, is highly diagnostic. The search for biomarkers of premotor PD in blood, cerebrospinal fluid, and urine has not uncovered any useful candidates. 10 Likewise, although positron emission tomography and single photon emission computed tomography imaging can visualize nigrostriatal nerve terminals of dopamine synthesis and identify presymptomatic pathology, their use remains investigational and largely confined to enriched populations of asymptomatic first-degree relatives of patients with PD.
10 Although these methods are highly sensitive and specific, the application of such imaging techniques into routine practice in asymptomatic at-risk individuals is not yet justified. Other associated premotor symptoms, such as hyposmia (a reduced ability to smell and detect odors) and rapid eye movement sleep disorder, are among the earliest symptoms to appear; screening for these findings may prove more economically practical and identify a population at higher risk and worthy of further study.
14 An example of such a strategy can be found in the longitudinal Parkinson Associated Risk Study (http://www.parsinfosource.com), which uses an inexpensive but sensitive screening test of olfactory disturbances to select asymptomatic individuals at risk for PD to undergo further neuroimaging. 10 Those with pathology identified from neuroimaging are then observed longitudinally for the development of motor symptoms. By the time patients present with symptoms such as L.M., a substantial burden of neuropathologic evidence has accumulated, and the diagnosis can be made clinically. Therefore, further laboratory or radiological testing is unnecessary. The classic features of PD-tremor, limb rigidity, and bradykinesia-are easily recognized, particularly in advanced stages of disease. However, it is important to note that not all are required to be present to make the diagnosis of PD. The presence of two or more features indicates clinically probable PD. 15 Tremor, which is most often the first symptom observed in younger patients, is usually unilateral on initial presentation. Frequently, the tremor is of a pill-rolling type involving the thumb and index finger (3-6 Hz); it is present at rest, worsens under fatigue or stress, and is absent with purposeful movement or when asleep.
Neurologic Disorders
1 These features help distinguish it from essential tremor, which usually manifests as a symmetric tremor in the hands, often accompanied by head and voice tremor.
12 Approximately 30% of patients with idiopathic PD do not present with tremor.
16 Muscular rigidity resulting from increased muscle tone often manifests as a cogwheel or ratchet (catch-release) type of motion when an extremity is moved passively.
1 Rigidity may also be experienced as stiffness or vague aching or limb discomfort. 12 Bradykinesia refers to an overall slowness in initiating movement. Early in the disease, patients may describe this as weakness or clumsiness of a hand or leg. 12 As the disease progresses, difficulty initiating and terminating steps results in a hurried or festinating gait; the posture becomes stooped (simian posture), and postural reflexes are impaired.
1 Symptoms that were unilateral on initial presentation progress asymmetrically and often become bilateral and more severe with disease progression.
1 Patients with PD develop masked facies, or a blank stare with reduced eye blinking ( Fig. 57-1 ). 1 Several conditions can be mistaken for PD, and include multiple system atrophy (formerly known as Shy-Drager syndrome), progressive supranuclear palsy, and normal pressure hydrocephalus. These atypical parkinsonian conditions (also referred to as "parkinsonplus" syndromes) are important to distinguish from PD because they respond poorly to dopaminergic medications and are associated with worse prognosis. 12 Magnetic resonance imaging can be useful in some situations to exclude these conditions, particularly when clinical signs suggest an alternate diagnosis. Falls or dementia early in the disease, symmetric parkinsonism, wide-based gait, abnormal eye movements, marked orthostatic hypotension, urinary retention, and marked disability within 5 years after the onset of symptoms suggest alternative diagnoses other than PD.
16 Drugs that act as antagonists at dopaminergic D 2 receptors (e.g., neuroleptics, prochlorperazine, and metoclopramide), and others such as valproate, amiodarone, phenytoin, and lithium may cause a state of drug-induced parkinsonism that mimics idiopathic PD. Drug-induced parkinsonism should be excluded before the diagnosis of PD is established. Although reversible, symptoms may persist for weeks or months after discontinuation of the offending agent.
16
L.M. presents with many of the classic symptoms of PD. A noticeable unilateral resting tremor is present along with decreased manual dexterity, as evidenced by his difficulty handling a paintbrush. Rigidity (ratcheting of the arms), bradykinesia (slowness of movement), and a masklike facial expression also are present. Although he has a partially stooped posture, it is difficult to attribute this entirely to the disease because postural changes commonly occur with advancing age and, on physical examination, his balance was normal. To confirm the diagnosis of PD, a therapeutic trial of levodopa may be considered. A positive response to levodopa, as evidenced by an improvement in motor or cognitive function, suggests the diagnosis of PD. Patients with the tremor-predominant form of the disease may, however, not respond to levodopa, especially in the early stages of the disease.
Numerous nonmotor clinical features are associated with PD. Handwriting abnormalities occur frequently, particularly micrographia, a symptom of bradykinesia. Because L.M. is an artist, this abnormality would be particularly troublesome. He also is showing signs of autonomic nervous system dysfunction, such as drooling (sialorrhea), seborrhea, and constipation, all of which can be particularly embarrassing to the patient. Drooling may be a consequence of impaired swallowing. The strong body odor exhibited by L.M. could be ascribed to excess sebum production. L.M.'s seborrhea can be treated with coal tar-or selenium-based shampoos, or topical ketoconazole. His constipation should be managed first by evaluating his diet and exercise level, discontinuing anticholinergic medications (including over-the-counter cold and sleep medications) that may exacerbate constipation, and using a stool softener such as sodium or calcium docusate. In more severe cases, polyethylene glycol, lactulose, milk of magnesia, or enemas may be required.
L.M. should be evaluated for other manifestations of autonomic dysfunction, including urinary problems, increased sweating, orthostatic hypotension, erectile dysfunction, pain or dysesthesias, and problems swallowing. L.M. has benign prostatic hypertrophy and may benefit from further evaluation. He should be counseled to avoid anticholinergic agents that may exacerbate this problem. He should be referred to a speech and swallowing expert because dysphagia can result in impaired swallowing and lead to aspiration; a soft diet may be indicated. The soft, mumbled, monotone voice noted in L.M. is frequently observed in PD and often one of the early symptoms noted. Speech therapy can be of benefit.
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Psychiatric disturbances, such as nervousness, anxiety, and depression, occur commonly in patients with PD, and regular screening for these symptoms should occur.
16,18 L.M. has a history of depression treated with citalopram that could be attributable to PD, and his therapy should be periodically evaluated. Finally, the prevalence of cognitive decline and dementia among patients with PD ranges from 10% to 30% and may be associated with a more rapid progression of disease-related disability.
7 The development of hallucinations in patients with PD with dementia is a poor prognostic sign. 19 The forgetfulness and decreased memory described by L.M. could be early signs of cognitive decline and warrant close observation. To assess the degree of disability and determine the rate of disease progression relative to treatment, various scales have been developed. The most common of these is the Hoehn and Yahr scale (Table 57-2). 2 In general, patients in Hoehn and Yahr stage 1 or 2 of PD have mild disease that does not interfere with activities of daily living or work and usually requires minimal or no treatment. In stage 3 disease, daily activities are restricted and employment may be significantly affected unless effective treatment is initiated. L.M. appears to be in late stage 2, early stage 3 of the disease according to the scale. Restricted to bed or wheelchair unless aided
Staging of Parkinson Disease
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With advanced-stage disease (3 to 4), most patients require levodopa therapy (with a peripheral decarboxylase inhibitor such as carbidopa) and often in combination with a COMT inhibitor such as entacapone or a dopamine agonist such as pramipexole or ropinirole. In some cases, selegiline, rasagiline, or amantadine may provide further symptomatic relief. Patients with endstage disease (stage 5) are severely incapacitated and, because of advanced disease progression, often do not respond well to drug therapy.
TREATMENT OF PARKINSON DISEASE
CASE 57-1, QUESTION 3: When should L.M. begin treatment for his PD?
In choosing when to treat the symptoms of PD and which therapy to use, care must be taken to approach each patient individually. Although no consensus has been reached about when to initiate symptomatic treatment, most health care professionals agree that treatment should begin when the patient begins to experience functional impairment as defined by (a) threat to employment status, (b) symptoms affecting the dominant side of the body, or (c) bradykinesia or rigidity. Individual patient preferences also should be considered. Judging by the symptoms L.M. is displaying, he would likely benefit from immediate treatment. His symptoms are unilateral but are occurring on his dominant side and are interfering with his ability to paint, thus affecting his livelihood. He is also showing signs of rigidity and bradykinesia but can otherwise live independently.
An algorithm for the management of patients with PD is presented in Figure 57- Neurologic Disorders plan is usually characterized by frequent dosage adjustments with time because of the chronic and progressive nature of the disease. Although most of this chapter is devoted to the drug therapy of PD, the importance of supportive care cannot be overemphasized. Exercise, physiotherapy, and good nutritional support can be beneficial at the earlier stages to improve mobility, increase strength, and enhance well-being and mood. 16 Psychological support is often necessary in dealing with depression and other related problems. Newly diagnosed patients and their family members need to be educated about what to expect from the disease and the various forms of treatment available. The support of family members is vital in establishing an overall effective therapeutic plan.
Dopamine Agonists
INITIAL THERAPY
CASE 57-1, QUESTION 4: The decision is made to begin drug therapy for L.M. Should therapy be initiated with a dopamine agonist or levodopa?
Levodopa remains the most effective antiparkinsonian agent. 12 However, monotherapy with levodopa throughout the entire course of the disease is limited by response fluctuations and declining efficacy as PD progresses. Escalating doses of levodopa are accompanied by a high frequency of undesirable side effects; thus, other methods of enriching dopamine supply have been developed. Dopamine agonists, which directly bind to dopamine receptors, are one such group of agents. In clinical trials comparing dopamine agonists with levodopa, activities of daily living (ADLs) and motor features are improved 40% to 50% with levodopa compared with 30% with dopamine agonists. 20 Although they are not as effective as levodopa, the dopamine agonists have a number of potential advantages. Because they act directly on dopamine receptors, they do not require metabolic conversion to an active product and therefore act independently of degenerating dopaminergic neurons. Unlike levodopa, circulating plasma amino acids do not compete with dopamine agonists for absorption and transport into the brain. Dopamine agonists have a longer half-life than levodopa formulations, reducing the need for multiple daily dosing. Initial therapy with dopamine agonists is associated with fewer motor complications such as dyskinesias, and can delay the need for initiation of dopaminergic therapy. [21] [22] [23] As a class, dopamine agonists provide adequate control of symptoms when given as monotherapy in up to 80% of patients with early-stage disease. These benefits are sustained for 3 years or more in most patients. However, with disease progression, levodopa therapy will eventually be required.
Guidelines from the American Academy of Neurology support either dopamine agonists or levodopa as initial therapy for PD. 24 In younger patients (e.g., age <65 years) with milder disease, such as L.M., the initiation of a dopamine agonist as a first-line agent is a strategy used to delay the introduction of levodopa. Delaying levodopa allows patients to have a longer period of time before experiencing motor complications, particularly troubling peak-dose levodopa-induced dyskinesias, which eventually develop with advancing PD. In older patients (e.g., age >65 years) with PD, it may be more appropriate to initiate treatment with levodopa instead of a dopamine agonist because these patients are more likely to experience intolerable central nervous system side effects from dopamine agonists.
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In the case of L.M., his relatively young age (<65 years) and mild disease make him a good candidate for initial therapy with a dopamine agonist. L.M. will require levodopa therapy at a later time, when he reaches more advanced stages of the disease. By initiating therapy first with a dopamine agonist, rescue levodopa therapy can likely be started at smaller doses, and the onset of motor complications that often occur with escalating doses and extended therapy with levodopa may be delayed.
SELECTION OF AGENTS
CASE 57-1, QUESTION 5: L.M. is to be started on a dopamine agonist. Which agent should be selected?
Two generations of dopamine agonists have been used for the treatment of idiopathic, early-stage PD as monotherapy, or as an adjunct to levodopa in patients with advanced disease. The comparative pharmacologic and pharmacokinetic properties of these agents are shown in Table 57 -3. The first-generation dopamine agonists, which are derived from ergot alkaloids, include bromocriptine, pergolide, and cabergoline. These older agents are now rarely used because of increased risk of retroperitoneal, pleural, and pericardial fibrosis, as well as a twofold to fourfold increased risk for cardiac valve fibrosis, when compared with nonergoline dopamine agonists and controls. 25, 26 Pergolide was voluntarily withdrawn in the United States in 2007 for this reason, and although cabergoline continues to be used in Europe, it is only indicated in the United States for treating hyperprolactinemia. Pramipexole, ropinirole, apomorphine, and rotigotine are second-generation nonergoline dopamine agonists. Of 31,32 These trials were multicenter, placebo-controlled, parallel-group studies, and the primary outcome measures included improvement in ADLs (part II) and motor function scores (part III) as measured by the Unified Parkinson Disease Rating Scale (UPDRS). (Go to http://www. mdvu.org/library/ratingscales/pd/ to download this document.) Each evaluation on the UPDRS is rated on a scale of 0 (normal) to 4 (can barely perform). Lower scores on the UPDRS after treatment indicate an improvement in overall performance.
The evidence for pramipexole's efficacy in early PD comes from two large-scale, double-blind, placebo-controlled studies that included a total of 599 patients with early-stage PD (mean disease duration of 2 years). 28, 29 In the first study, 264 patients were randomly assigned to receive one of four fixed doses (1.5, 3.0, 4.5, or 6.0 mg/day) or placebo. 28 The pramipexole-treated patients had a 20% reduction in their total UPDRS scores compared with baseline values, whereas no significant improvement was observed in the placebo-treated patients. A trend toward decreased tolerability was noted as the pramipexole dosage was escalated, especially in the 6.0-mg/day group. A second study of 335 patients titrated doses up to the maximal tolerated dose (not to exceed 4.5 mg/day) and then followed patients for a 6-month maintenance phase. 29 The mean pramipexole maintenance dosage was 3.8 mg/day. Those treated with pramipexole experienced significant improvements in both the ADL scores (22%-29%) and motor scores (25%-31%), whereas there were no significant changes in the placebo group (p <0.0001) .
Against levodopa as initial therapy, pramipexole appears to delay the onset of dyskinesias. In a randomized, controlled trial evaluating the development of motor complications with the two therapies, 301 untreated patients with early PD were randomly assigned to receive either pramipexole 0.5 mg three times daily or carbidopa/levodopa 25/100 mg three times daily.
23 Doses could be escalated during the first 10 weeks of the study, after which open-label levodopa was permitted if necessary. The primary end point was the time to the first occurrence of wearing off, dyskinesias, or on-off motor fluctuations. After a mean follow-up of 24 months, patients in the pramipexole group were receiving a mean daily dose of 2.78 mg pramipexole and 264 mg of supplemental levodopa, whereas patients in the levodopa group were receiving a mean total of 509 mg/day levodopa. Fewer pramipexole-treated patients reached the primary end point (28% vs. 51%; p <0.001) than the patients initially randomly assigned to levodopa therapy. Dyskinesias were noted in only 10% of pramipexole-treated patients compared with 31% of levodopa-treated patients (p <0.001), and fewer patients experienced wearing-off effects with pramipexole (24% vs. 38%; p = 0.01). Long-term follow-up of this cohort (mean = 6.0 years) has revealed a persistently lower rate of dopaminergic motor complications in the pramipexole-treated patients compared with those receiving levodopa (50.0% vs. 68.4%, respectively; p = 0.002).
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ROPINIROLE
Ropinirole is a synthetic nonergoline dopamine agonist with selectivity for D 2 receptors; as with pramipexole, however, it has no significant affinity for D 1 receptors.
34 Although the drug is pharmacologically similar to pramipexole, it has some distinct pharmacokinetic properties, as shown in Table 57 -3. Unlike pramipexole, which is primarily eliminated by renal excretion, ropinirole is metabolized by the cytochrome P-450 (primarily CYP1A2) oxidative pathway and undergoes significant firstpass hepatic metabolism.
35 Similar to pramipexole, ropinirole is approved for use as monotherapy in early-stage idiopathic PD and as an adjunct to levodopa therapy in patients with advancedstage disease.
Ropinirole has not been directly compared with pramipexole in a randomized, double-blind trial, but it appears to have comparable efficacy as inferred from indirect comparison. In several randomized, double-blind, multicenter, parallel group studies comparing it with placebo, bromocriptine, or levodopa, 6 months of monotherapy with ropinirole in patients with early PD significantly improves UPDRS motor scores (approximately 20%-30%) compared with baseline values. [36] [37] [38] In a long-term study, patients treated initially with ropinirole were less likely to experience dyskinesias compared with those treated initially with levodopa.
21 At the end of 5 years, the mean daily dose of ropinirole was 16.5 mg plus 427 mg of open-label levodopa, compared with a mean daily dose of 753 mg of levodopa for the levodopa group. Of patients in the ropinirole group, 66% required open-label levodopa supplementation compared with 36% in the levodopa group. Dyskinesias developed in 20% of the ropinirole-treated patients compared with 45% of the levodopatreated patients (hazard ratio for remaining free of dyskinesia in the ropinirole group, compared with the levodopa group, 2.82; p <0.001). For ropinirole-treated patients who were able to remain on monotherapy without open-label levodopa supplementation, only 5% experienced dyskinesia, compared with 36% of those receiving levodopa monotherapy. The lower incidence of dyskinesia in ropinirole-treated patients was shown to persist in long-term open-label follow-up of this study cohort. Pramipexole and ropinirole should always be initiated at a low dosage and gradually titrated to the maximal effective dose, as tolerated. This approach minimizes adverse effects that may result in nonadherence or discontinuation of the drug. In clinical trials, the maximal effective doses are variable and correlate with disease severity and tolerability. One fixed-dose study of pramipexole in early PD showed that most patients responded maximally at a dosage of 0.5 mg three times daily. 29 In patients with advanced-stage disease, an average of 3.4 mg/day is usually required to reach the maximal effect of pramipexole. 32 L.M. has normal renal function and his pramipexole should be started at an initial dosage of 0.125 mg three times daily for 5 to 7 days. At week 2, the dosage should be increased to 0.25 mg three times daily. Thereafter, his dosage may be increased weekly by 0.25 mg/dose (0.75 mg/day) as tolerated and up to the maximal effective dose, not to exceed 1.5 mg three times daily. 40 The titration period usually takes about 4 to 7 weeks, depending on the optimal maintenance dose. Patients with a creatinine clearance of less than 60 mL/minute should be dosed less frequently than those with normal renal function. 40 Patients with a creatinine clearance of 35 to 59 mL/minute should receive a starting dose of 0.125 mg twice daily up to a maximal dose of 1.5 mg twice daily; patients with a creatinine clearance of 15 to 34 mL/minute should receive a starting dose of 0.125 mg daily up to a maximal dose of 1.5 mg daily. Pramipexole has not been studied in patients with a creatinine clearance of less than 15 mL/minute or those receiving hemodialysis. A once-daily extended-release formulation of pramipexole is also available; patients can be switched overnight from immediate-release pramipexole at the same daily dose.
Ropinirole should be initiated at a dosage of 0.25 mg three times daily with gradual titration in weekly increments of 0.25 mg/dose over the course of 4 to 6 weeks. 41 Clinical response to ropinirole is usually observed at a daily dose of 9 to 12 mg given in three divided doses. Doses may be increased to a maximal daily dose of 24 mg/day. Patients wishing to take the drug less frequently can be switched directly to an extended-release oncedaily formulation, selecting the dose that most closely matches the total daily dose of the immediate-release formulation. No dose adjustments for ropinirole are necessary in patients with renal dysfunction.
ADVERSE EFFECTS
CASE 57-1, QUESTION 8: What are the adverse effects of pramipexole and ropinirole? How can these be managed?
Because pramipexole and ropinirole are both approved for use as monotherapy in early-stage disease and as adjunctive therapy in advanced-stage disease, the adverse events of these agents have been evaluated as a function of disease stage. In studies of patients with early-stage disease, the most common adverse effects were nausea (∼28%-44%), dizziness (∼25%-40%), somnolence (∼22%-40%), insomnia (∼17%), constipation (∼14%), asthenia (∼14%), hallucinations (∼9%), and leg edema (∼5%). [28] [29] [30] [36] [37] [38] 40 ,41 Nausea, with or without vomiting, can be a significant problem, particularly with higher doses. Administering these drugs with food may partially alleviate this problem. With continued use, many patients exhibit tolerance to the gastrointestinal side effects. Central nervous system side effects were the most common reason for discontinuation of these agents. Older patients are particularly more likely to experience hallucinations and other central nervous system adverse effects with dopamine agonists. The incidence of orthostatic hypotension was relatively low (1%-9%) and may in part reflect the exclusion of patients with underlying cardiovascular disease in several of the studies.
In advanced-stage disease, the most common adverse events of dopamine agonists were nausea (25%), orthostatic hypotension (10%-54%), dyskinesias (26%-47%), insomnia (27%), somnolence (11%), confusion (10%), and hallucinations (11%-17%). 32, [40] [41] [42] As expected, in patients with advanced-stage disease, the most common reasons for discontinuing these agents are mental disturbances (nightmares, confusion, hallucinations, insomnia) and orthostatic hypotension. Dyskinesias experienced when dopamine agonists are used in combination with levodopa in advanced-stage disease may require lowering the dose of levodopa or, in some cases, the dopamine agonist.
Sudden, excessive daytime somnolence, including while driving, has been reported with dopamine agonists and has resulted in accidents. 40, 41, 43 Affected patients have not always reported warning signs before falling asleep and believed they were alert immediately before the event. Labeling for these drugs includes a warning that patients should be alerted to the possibility of falling asleep while engaged in daily activities. Patients should be advised to refrain from driving or other potentially dangerous activities until they have gained sufficient experience with the dopamine agonist to determine whether it will hinder their mental and motor performance. Caution should be advised when patients are taking other sedating medications or alcohol in combination with pramipexole and ropinirole. If excessive daytime somnolence does occur, patients should be advised to contact their physician.
Dopamine agonist therapy in patients with PD is associated with a 2-to 3.5-fold increased odds of developing an impulse control disorder.
44 The frequency appears similar for both pramipexole and ropinirole. In one study, a prevalence of 6.1% was noted for pathologic gambling in patients with PD compared with 0.25% for age-and sex-matched controls. 45 These cases may represent variations of a behavioral syndrome termed hedonistic homeostatic dysregulation or dopamine dysregulation syndrome.
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Other features of the syndrome have been reported, including punding (carrying out repetitive, purposeless motor acts), hypersexuality, walkabout (having the urge to walk great distances during on times, often with no purpose or destination and abnormalities in time perception), compulsive buying, binge eating, drug hoarding, and social independence or isolation. 46 The syndrome appears to be more common among younger, male patients with early-onset PD, as well as those having novelty-seeking personality traits, depressive symptoms, and current use of alcohol or tobacco. 44, 47 Management of impulse control disorders can be challenging, as it often requires modification of dopaminergic therapies, which must be carefully balanced with the accompanying risk of worsening motor function. Underlying depression, if present, should be treated and may improve impulse control. Nonpharmacologic measures (such as limiting access to money or the Internet) may be helpful; in some cases, antipsychotic drugs may be considered, but must also be used carefully to avoid precipitating motor disability.
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Although L.M. is younger than 65 years of age, he is experiencing memory difficulty and may be at increased risk for visual hallucinations and cognitive problems from dopamine agonist therapy. He should be monitored closely for occurrence or exacerbation of these problems. He should also be evaluated for lightheadedness before initiation of pramipexole and counseled to report dizziness or unsteadiness, because this may lead to falls. He should also be reassured that if these effects are caused by pramipexole, they should subside with time and that he should not drive or operate complex machinery until he can assess the drug's effect on his mental status. L.M. should be counseled about the possibility of excessive, and potentially unpredictable, daytime somnolence as pramipexole is introduced. L.M. does
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not appear to have a problem with excessive alcohol use; however, he and his family should be educated about his increased risk for impulse control disorders and advised to report any new, unusual or uncharacteristic behaviors or increased use of alcohol.
ROTIGOTINE CASE 57-1, QUESTION 9: What type of dopamine agonist is rotigotine? How is it used?
Rotigotine is a nonergoline dopamine receptor agonist that was briefly available in the United States for the treatment of early-stage idiopathic PD. It remains available in Europe. Rotigotine is formulated in a transdermal patch delivery system designed for once a day application. Transdermal delivery may provide a more continuous stimulation of dopamine receptors than traditional oral formulations, which in theory may translate into improved efficacy. Rotigotine has demonstrated efficacy as monotherapy in early-stage PD, [49] [50] [51] and as adjunctive therapy to levodopa in patients with advanced stages of PD.
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Adverse events with rotigotine were similar to those observed with other dopamine agonists (nausea, vomiting, somnolence, dizziness).
Rotigotine was voluntarily withdrawn from the US market in 2008 because of problems with crystal formation in the patches, and faces an uncertain future. Although it continues to be available in Europe, no timeline has been given for its reintroduction into the United States.
Levodopa
TIMING OF INITIATION OF THERAPY
CASE 57-1, QUESTION 10: L.M. has responded well to pramipexole 1.0 mg three times daily (TID) for the past 18 months, with an increased ability to paint and carry out ADLs. During the past few weeks, however, he has noticed a gradual worsening in his symptoms and once again is having difficulty holding a paintbrush. He currently complains of feeling more "tied up," he has more difficulty getting out of a chair, and his posture is slightly more stooped. He also notes that he feels tired throughout much of the day. He remains able to carry out most of his ADLs without assistance. Should levodopa be considered for the treatment of L.M.'s PD at this time?
Dopamine itself does not cross the blood-brain barrier. Levodopa, a dopamine precursor with no known pharmacologic action of its own, crosses the blood-brain barrier, where it is converted by aromatic amino acid (dopa) decarboxylase to dopamine. For patients with advancing PD, levodopa has been a mainstay of treatment since the 1960s. 53 Nearly all patients will eventually require treatment with the drug, regardless of their initial therapy. Although it is the most effective therapy for treating the rigidity and bradykinesia of PD, as with other dopaminergic agents, levodopa does not effectively improve postural instability, or reduce dementia, autonomic dysfunction, or freezing, an extreme type of akinesia that often occurs in advanced-stage disease.
The question of when to begin levodopa in the treatment of PD has been historically debated. With long-term use, the efficacy of levodopa decreases (as measured by the total on time), and the development of motor fluctuations and dyskinesias occurs. These observations led to the belief that chronic levodopa therapy may actually accelerate the neurodegenerative process through formation of free radicals generated by dopamine metabolism. 54 The Earlier versus Later Levodopa Therapy in Parkinson's Disease (ELLDOPA) study was designed to determine whether long-term use of levodopa accelerates neurodegeneration and paradoxically worsens PD. 55 The investigators of this study randomly assigned 361 patients with early PD to either carbidopa/levodopa 37.5/150 mg/day, 75/300 mg/day, or 150/600 mg/day or placebo for 40 weeks followed by a 2-week withdrawal of treatment. After 42 weeks, the severity of symptoms as measured by changes in the total UPDRS increased more in the placebo group than in all of the groups receiving levodopa. The findings of this study provide assurance that levodopa use does not result in accelerated progression of the disease based on clinical evaluations.
The optimal time to initiate levodopa therapy must be individualized. In untreated individuals, there is little reason to start levodopa until the patient reports worsening of function (socially, vocationally, or otherwise). As discussed previously, the need for levodopa therapy may be delayed by initiating therapy first with a dopamine agonist. This approach is a particular advantage in younger patients who will likely live many years with PD. In the case of L.M., he is now experiencing bothersome symptoms despite near-maximal dopamine agonist therapy, and it has progressed sufficiently to threaten his job performance. Although the dose of pramipexole could be increased, he may experience more daytime somnolence; thus, levodopa should be added to his regimen.
LEVODOPA: ADVANTAGES AND DISADVANTAGES
CASE 57-1, QUESTION 11: What are the advantages and disadvantages of carbidopa/levodopa versus levodopa alone?
Although levodopa is the most effective agent for PD, it is associated with many undesirable side effects, such as nausea, vomiting, and anorexia (50% of patients); postural hypotension (30% of patients); and cardiac arrhythmias (10% of patients). 12 In addition, mental disturbances (see Case 57-1, Question 13) are encountered in 15% of patients, and abnormal involuntary movements (dyskinesias) can be seen in up to 55% of patients during the first 6 months of levodopa treatment.
56 Because significant amounts of levodopa are peripherally (extracerebrally) metabolized to dopamine by the enzyme aromatic amino acid (dopa) decarboxylase, extremely high doses are necessary if administered alone. For this reason, levodopa is always coadministered with a dopa decarboxylase inhibitor.
By combining levodopa with a dopa decarboxylase inhibitor that does not penetrate the blood-brain barrier, a decrease in the peripheral conversion of levodopa to dopamine can be achieved, while the desired conversion within the basal ganglia remains unaffected (Fig. 57-3) . 57 The two peripheral decarboxylase inhibitors in clinical use are benserazide (unavailable in the United States) and carbidopa. A fixed combination of carbidopa and levodopa is available in ratios of 1:4 (carbidopa/levodopa 25/100) and 1:10 (carbidopa/levodopa 10/100 and 25/250). A controlled-release product is available in a ratio of 25/100 and 50/200. In addition, carbidopa/levodopa is also available as an orally disintegrating tablet.
Combining carbidopa with levodopa enhances the amount of dopamine available to the brain and thereby allows the dose of levodopa to be decreased by 80%. 58 This combination also shortens the time needed to achieve optimal effects by several weeks, because carbidopa substantially decreases the often doselimiting levodopa-induced nausea and vomiting. About 75 to 100 mg/day of carbidopa is necessary to saturate peripheral dopa decarboxylase. 16 It is usually unnecessary and more costly to give higher amounts of carbidopa than this. Therapy should be initiated with immediate-release carbidopa/levodopa 25/100 at a dose of one tablet three times a day. The immediate-release formulation is preferred because it allows for much easier adjustment of the levodopa dose. In L.M.'s case, the dose can then be increased by 100 mg of levodopa every day or every other day up to eight tablets (800 mg) or to the maximal effective dose, to individual requirements, or as tolerated.
If troublesome peak-dose dyskinesias occur, the following strategies should be considered: the levodopa dose can be lowered but given more frequently; consideration can be given to switching patients to immediate-release if taking controlledrelease carbidopa/levodopa (for ease in refining dose adjustments); agents that prolong the half-life of levodopa but do not provide stable levodopa plasma concentrations (e.g., COMT inhibitor, MAO-B inhibitor) can be added; or an antidyskinetic agent such as amantadine can be used. The goal of optimizing therapy lies in balancing the most useful dose (i.e., maximizing the patient's on time) with that which does not produce unacceptable side effects (i.e., troublesome dyskinesias). Because L.M. is currently being treated with a dopamine agonist, he must be monitored closely for the development of motor complications with the addition of levodopa.
Most patients respond to levodopa doses of 750 to 1,000 mg/ day when given with carbidopa. 16 When levodopa doses exceed 750 mg/day, patients such as L.M. can be switched from the 1:4 ratio of carbidopa/levodopa to the 1:10 ratio to prevent providing excessive amounts of decarboxylase inhibitor. For example, if L.M. needed 800 mg/day of levodopa, two carbidopa/levodopa 10/100 tablets four times daily could be given. If L.M. had not been initially treated with a dopamine agonist, some clinicians would consider adding a dopamine agonist after the daily levodopa dose has been increased to more than 600 mg because dopamine agonists directly stimulate dopamine receptors, have longer half-lives, and result in a lower incidence of dyskinesias, thus providing a smoother dopaminergic response. 16 L.M.'s clinical response to levodopa therapy may be improved by modifying dietary amino acid ingestion. 16, 59 Levodopa is actively transported across the blood-brain barrier by a large neutral amino acid transport system. This transport system also facilitates the blood-to-brain transport of amino acids such as l-leucine, l-isoleucine, l-valine, and l-phenylalanine. Levodopa and these neutral amino acids compete for transport mechanisms, and high plasma concentrations of these amino acids can decrease brain concentrations of levodopa. 59 Patients should be instructed to take immediate-release carbidopa/levodopa 30 minutes before or 60 minutes after meals for optimal efficacy.
ADVERSE EFFECTS: MENTAL CHANGES
CASE 57-1, QUESTION 13: Since initiating carbidopa/ levodopa, L.M. reports he feels confused at times and has Chapter 57 trouble remembering recent events. To what extent is levodopa contributing to confusion and memory problems? How should they be managed?
Although more commonly encountered with dopamine agonists, psychiatric side effects are also associated with levodopa therapy, and include confusion, depression, restlessness and overactivity, psychosis, hypomania, and vivid dreams. 60 Those with underlying or pre-existing psychiatric disorders and those receiving high doses of levodopa for prolonged periods are at greatest risk.
60 Concurrent anticholinergics or amantadine therapy can exacerbate these symptoms. Advancement of the PD itself correlates with cognitive decline and greater frequency of central nervous system findings, likely mediated through the underlying Lewy body pathology. In some situations it may be difficult to separate the respective drug versus disease effects.
Some patients receiving levodopa experience psychomotor excitation. Symptoms associated with psychomotor activation include overactivity, restlessness, and agitation. Similarly, hypomania has been reported in up to 8% of patients and is characterized by grandiose thinking, flight of ideas, tangential thinking, and poor social judgment. Normal sexual activity often is restored with improved motor function; however, hypersexuality and libido are increased in about 1% of levodopa-treated patients.
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In general, most of the mental disturbances are dose-related and can be lessened by reducing the dose of the dopaminergic agent. In patients such as L.M. who are concurrently receiving levodopa and a dopamine agonist, the dose reduction should be attempted first with the dopamine agonist. If symptoms do not improve, a reduction in the dose of the levodopa may also be warranted. These dose reductions may, however, be impractical for L.M. because a return of parkinsonian symptoms is likely, and the benefits of levodopa therapy may outweigh the risk for mental disturbances.
Motor Complications
CASE 57-1, QUESTION 14: L.M. had a dramatic improvement in all of his parkinsonian symptoms with the initiation of levodopa therapy after being maintained on 25/250 regular carbidopa/levodopa four times a day.
For a video showing an example of the effects of dopaminergic medication on the mobility of a Parkinson patient, go to http://thepoint.lww.com/AT10e.
After 6 months of treatment, he began to experience dyskinesias. These usually occurred 1 to 2 hours after a dose and were manifested by facial grimacing, lip smacking, tongue protrusion, and rocking of the trunk. These dyskinetic effects were lessened by decreasing his pramipexole dose to 0.5 mg TID and gradually decreasing his dosage of carbidopa/levodopa to 25/250 TID.
After 3 years of levodopa therapy, more serious problems have begun to emerge. In the mornings, L.M. often experiences immobility. Nearly every day, he has periods (lasting for a few minutes) in which he cannot move, followed by a sudden switch to a fluidlike state, often associated with dyskinetic activity. He continues to take carbidopa/levodopa (25/250 TID), but gains symptomatic relief only for about 3 to 4 hours after a dose. Also, the response to a given dose varies and is often less in the afternoon. At times, he becomes "frozen," particularly when he needs to board an elevator or is required to move quickly.
What are possible explanations for these alterations in clinical response?
For most patients, the initial response to levodopa is favorable, and this early phase is called the honeymoon period. Although variable in each patient, the honeymoon period can last for up to 5 years. After this initial period of stability, 50% to 90% of patients with PD receiving levodopa for 5 or more years will eventually experience motor complications. 16 In evaluating response fluctuations, it is important to ascertain which effects are attributable to the disease and which are attributable to the drug. Levodopainduced dyskinesias often appear concurrently with the development of motor fluctuations.
16 Peak-dose choreiform dyskinesias are the most common form of dyskinesias that occur with chronic levodopa (and sometimes dopamine agonist) therapy and they frequently subside at the end of the dosing interval. Their severity is related to levodopa dose, disease duration and stage, and younger age at onset. 61 Reducing the levodopa dosage will often reverse these symptoms. However, the reduction in levodopa dosage usually results in deterioration in the control of the disease.
Because levodopa is a short-acting agent with an elimination half-life of about 1.5 hours, much of the effect from the evening dose has dissipated by morning.
58 For this reason, it is not surprising that L.M. is experiencing a period of immobility on arising. This is alleviated in most patients shortly after taking the morning dose.
Two of the more common motor complications are the on-off effect and the wearing off, or end-of-dose deterioration effect. The on-off effect is described as random fluctuations from mobility (often associated with dyskinesias) to the parkinsonian state, which appear suddenly as if a switch has been turned on or off. These fluctuations can last from minutes to hours and increase in frequency and intensity with time. Although most patients prefer to be on despite accompanying dyskinesias, rather than in an off or akinetic state, dyskinesias in some patients can be more disabling than the parkinsonism. 16 Early in the course of disease, it is usually possible to adjust the amount and timing of the doses of levodopa to control parkinsonian symptoms without inducing dyskinesias; however, as the disease advances and the therapeutic window narrows, cycling between on periods complicated by dyskinesia and off periods with resulting immobility is common. 16 Eventually, despite adjustments in levodopa dose, many patients with advanced PD experience either mobility with severe dyskinesias or complete immobility. In most patients, this effect bears no clear relationship to the timing of the dose or levodopa serum levels. 62 The wearing off or end-of-dose effect is a more predictable effect that occurs at the latter part of the dosing interval after a period of relief; it can be improved by various means such as shortening the dosing interval or by adjunctive therapy with a dopamine agonist (if not already present) or levodopa extender such as a COMT inhibitor.
The pathophysiologic basis for motor complications and dyskinesias is not entirely clear, but incomplete delivery of dopamine to central receptors is likely responsible. 61 As the disease progresses, dopamine terminals are lost and the capacity to store dopamine presynaptically is diminished. 61 This dopaminergic denervation impairs the ability to maintain striatal dopamine concentrations at a relatively constant level. As a consequence, dopamine receptors are subject to intermittent or pulsatile stimulation rather than by a more natural physiologic tonic stimulation. Overactivity of excitatory pathways mediated by neurotransmitters such as glutamate may also be involved. CONTROLLED-RELEASE CARBIDOPA/LEVODOPA A more sustained delivery of levodopa than that achieved with routine oral dosing has been suggested to reduce motor complications, because it would more effectively replicate normal physiology. Several studies have documented the efficacy of continuous infusions of levodopa in patients with advanced PD, 63, 64 but this strategy is not widely used outside of research protocols. A controlled-release formulation of carbidopa/levodopa is available, containing 25 mg carbidopa and 100 mg levodopa or 50 mg carbidopa and 200 mg levodopa in an erodible polymer matrix that retards dissolution in gastric fluids. Although off time should theoretically be reduced by the slower rate of plasma levodopa decline, clinical study has generally not found a difference in off time, or a reduction in dyskinesias, with the controlled-release preparation compared with the immediate-release preparation.
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As a result, the American Academy of Neurology Practice Parameter for treatment of motor fluctuations and dyskinesias does not recommend switching to controlled-release carbidopa/levodopa as a primary strategy to reduce off time or lessen dyskinesias.
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A likely reason for the lack of superior effect with controlledrelease carbidopa/levodopa as compared with the regular release formulation is its variable absorption. Controlled-release carbidopa/levodopa is about 30% less bioavailable than the immediate-release formulation. Patients converted from standard carbidopa/levodopa to the controlled-release formulation should receive a dose that will provide 10% more levodopa, and then the dose should be titrated upward to clinical reponse.
16
Given that there is no obvious advantage to controlled-release carbidopa/levodopa, L.M.'s levodopa formulation should not be switched. Rather, L.M.'s condition may be improved by taking his immediate-release carbidopa/levodopa more frequently and avoiding substantial increases in the total daily dose, which could worsen his dyskinesias. Taking his morning dose before arising from bed may help with his early morning problems and prevent other response fluctuations. If L.M.'s symptoms are not improved with adjustment of his carbidopa/levodopa dose, a number of adjunctive agents such as dopamine agonists, apomorphine rescue, COMT inhibitors, and MAO-B inhibitors can be considered.
DOPAMINE AGONISTS
The effectiveness of pramipexole added to levodopa therapy in advanced PD was evaluated in a multicenter, placebo-controlled study of 360 patients with a mean disease duration of 9 years.
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Pramipexole was titrated gradually to the maximal effective dose as tolerated, and doses did not exceed 4.5 mg/day in three divided doses. At the end of a 6-month maintenance period, patients treated with pramipexole had a 22% improvement in their ADLs (p <0.0001) and a 25% improvement in their motor scores (p <0.01) compared with baseline values. Patients treated with pramipexole also had a 31% improvement in the mean off time, compared with a 7% improvement in the placebo-treated group (p <0.0006). Dyskinesias and hallucinations were more common in pramipexole-treated patients, and necessitated levodopa dose reduction in 76% of the pramipexole group compared with 54% in the placebo group. The total daily levodopa dose was decreased by 27% in those treated with pramipexole compared with 5% in the placebo group.
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Ropinirole has also shown efficacy in improving motor scores when added to levodopa therapy in patients with advanced-stage disease. 42 In a multicenter, double-blind, randomized parallelgroup study, patients treated with ropinirole experienced an average off time that was decreased by 1.9 hours daily. In those treated with ropinirole, the total daily levodopa dose was decreased by an average of 19%. At least a 35% reduction in off time and a reduction in levodopa dose were observed for 28% of ropinirole-treated patients, compared with 13% of those in the placebo group. In a study of 208 PD patients not optimally controlled with levodopa after up to 3 years of therapy with less than 600 mg/day of levodopa, a prolonged-release, once-daily formulation of ropinirole was found to improve motor scores in a similar fashion to increasing the levodopa dose; however, only 3% of ropinirole-treated subjects experienced dyskinesias compared with 17% of levodopa-treated patients (p <0.001).
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In moderate-to-advanced PD, treatment benefits were observed within 2 weeks of initiation.
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Because L.M. has advanced disease and is experiencing motor fluctuations despite a treatment regimen that includes a dopamine agonist, further dose adjustments of the dopamine agonist may provide little additional benefit. Any adjustments must be made with consideration of worsening his dyskinesias, and the possibility of exacerbating central nervous system adverse effects.
APOMORPHINE
Apomorphine is a dopamine agonist that is approved as rescue therapy for treatment of hypomobility or off episodes in patients with PD. It is available only in injectable form. In a randomized, double-blind, parallel-group study of 29 patients, rescue treatment with apomorphine resulted in a 34% reduction (∼2 hours) in off time compared with 0% in the placebo group (p = 0.02).
69 Mean UPDRS motor scores were reduced by 23.9 points (62%) in those treated with apomorphine, compared with 0.1 (1%) in those receiving placebo (p <0.001). Adverse events in the apomorphine group included yawning (40%), dyskinesias (35%), drowsiness or somnolence (35%), nausea or vomiting (30%), and dizziness (20%), although only yawning was statistically different from placebo (40% vs. 0%; p = 0.03).
Because nausea and vomiting frequently occur with apomorphine treatment, it should be administered with an antiemetic such as trimethobenzamide. The antiemetic should be started 3 days before initiating apomorphine and continued for the first 2 months of treatment.
70 Apomorphine should not be used with ondansetron and other serotonin antagonists used to treat nausea because the combination may cause severe hypotension. In addition, other antiemetics, such as prochlorperazine and metoclopramide, should not be given concurrently with apomorphine because they are dopamine antagonists and can decrease the effectiveness of apomorphine.
Doses of apomorphine range from 2 to 6 mg per subcutaneous injection. A 2-mg test dose is recommended while monitoring blood pressure. If tolerated, the recommendation is to start with a dose of 1 mg less than the tolerated test dose, and increase the dose by 1 mg every few days if needed. Peak plasma levels are observed within 10 to 60 minutes after dosing, so the onset of therapeutic effect is rapid. Two main disadvantages of apomorphine are that the test dose and titration are time-consuming and must be done under physician supervision, and that patients may require someone else to inject the drug once hypomobility has occurred. For these reasons, apomorphine is not widely used. Given that L.M. is experiencing motor fluctuations almost daily, long-term frequent apomorphine use would not be a viable solution in his situation.
AMANTADINE
The antiviral agent, amantadine, was serendipitously found to improve PD symptoms when a patient given the drug for influenza experienced a remission in her parkinsonism. 71 Amantadine reduces all the symptoms of parkinsonian disability in about 50% of patients, usually within days after starting therapy; however, long-term use is limited in many patients by the development of tachyphylaxis within 1 to 3 months.
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The pathophysiologic basis for amantadine's benefit in PD is not entirely understood, but it probably augments dopamine release from presynaptic nerve terminals and possibly inhibits dopamine reuptake into storage granules.
73 Anticholinergic action has also been suggested. More recently, amantadine has been found to be an antagonist at N-methyl-d-aspartate (NMDA) receptors and to block glutamate transmission. 74 Because excess glutamatergic activity has been implicated in the pathophysiology of dopaminergic dyskinesias, the finding of NMDA antagonism by amantadine has shifted its emphasis from use as monotherapy in early disease to that of an adjunctive agent in managing levodopa-induced dyskinesias. In several studies, amantadine has consistently shown approximately 50% reductions in dyskinesia severity and duration, without adversely impacting motor performance. [75] [76] [77] [78] The long-term efficacy of this approach has been questioned; however, a recent study indicates benefit can persist beyond 1 year.
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The decision to use amantadine in L.M. should be based on whether his dyskinesias are deemed more problematic than his duration of off time. If so, amantadine should be started 100 mg/ day taken at breakfast; an additional 100-mg can be taken with lunch 5 to 7 days after initiation. The dose can be increased to a maximum of 300 mg/day; however, doses in excess of 200 mg/ day are associated with increased adverse effects and should be used cautiously. Amantadine is renally excreted, and the dose should be reduced in patients with renal impairment. 80 If L.M.'s dyskinesias are tolerable but the duration of off time is more problematic, then selection of another agent such as a COMT inhibitor (discussed subsequently) may be more appropriate than instituting amantadine at this time.
Side effects of amantadine mainly involve the gastrointestinal (nausea, vomiting) and central nervous systems (dizziness, confusion, insomnia, nightmares, and hallucinations). Amantadine possesses anticholinergic properties, and patients receiving concomitant anticholinergic therapy may experience more prominent central nervous system side effects.
80 Livedo reticularis, a rose-colored mottling of the skin usually involving the lower extremities, can occur with amantadine as early as 2 weeks after initiating therapy. It is believed to be caused by local release of catecholamines, which lead to vasoconstriction and alter the permeability of cutaneous blood vessels. The consequences of livedo reticularis are entirely cosmetic and discontinuation of therapy is unnecessary. Ankle edema may be seen in association with livedo reticularis. Elevation of the legs, diuretic therapy, and dosage reduction often alleviate the edema.
CATECHOL-O-METHYLTRANSFERASE INHIBITORS
COMT is an enzyme widely distributed throughout the body, and it is responsible for the biotransformation of many catechols and hydroxylated metabolites, including levodopa. When carbidopa, an inhibitor of aromatic AAD, is coadministered with levodopa, the peripheral conversion of levodopa to dopamine via this pathway is inhibited; as a consequence, the conversion of levodopa to 3-O-methyldopa (3-OMD) by COMT is amplified and becomes the major metabolic pathway for levodopa degradation. The metabolite 3-OMD lacks antiparkinsonian activity and may compete with levodopa for transport into the circulation and brain. The therapeutic effect of levodopa can be extended by preventing its peripheral degradation though inhibition of COMT. Entacapone and tolcapone are selective, reversible, and potent COMT inhibitors that increase the amount of levodopa available for transport across the blood-brain barrier (Fig. 57-4 ). This effect prolongs the response to levodopa as measured by an increase in the amount of on time and a decrease in the daily levodopa dose. 81 The pharmacologic and pharmacokinetic effects of entacapone and tolcapone are compared in Table 57 -5. Tolcapone is slightly more potent and has a longer duration of action than entacapone. 82, 83 Entacapone is usually given with every administration of carbidopa/levodopa (up to eight tablets per day), whereas tolcapone is dosed three times daily. Tolcapone is associated with cases of fatal, acute fulminant liver failure, which has led to stringent liver function monitoring requirements and limited clinical use. If initiated, liver function monitoring should be performed at baseline and every 2 to 4 weeks for the first 6 months, followed periodically thereafter as clinically necessary. 84 Because of the risks for hepatotoxicity associated with tolcapone, entacapone is the preferred COMT inhibitor and would be a good choice for L.M. if he desires an increase in his on time. Entacapone has a Level A evidence recommendation to reduce off time in the American Academy of Neurology Practice Parameter addressing the treatment of motor fluctuations and dyskinesias. 66 
ENTACAPONE
CASE 57-1, QUESTION 16: Six months after adjusting the frequency of his carbidopa/levodopa and adding amantadine, L.M. reports that his dyskinesias are not too bothersome, but he is having increased periods (lasting a few minutes) in which he cannot move. He is currently taking 
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amantadine 100 mg twice daily, pramipexole 0.5 mg TID, and immediate-release carbidopa/levodopa 25/250 five times a day, but "even on a good day" gains symptomatic relief for only about 2 to 3 hours after a dose. The decision is made to initiate entacapone therapy and gradually discontinue pramipexole as symptoms or side effects demand. How effective is entacapone for reducing the symptoms of PD?
The efficacy and safety of entacapone as an adjunct to levodopa therapy was established in two pivotal multicenter, randomized, double-blind, placebo-controlled trials. 85, 86 Subjects for both studies had idiopathic PD with motor fluctuations, including wearing off phenomena, despite maximal tolerated doses of levodopa. In the first study, 171 patients were randomly assigned to receive either entacapone 200 mg or placebo (4-10 doses per day) with each dose of carbidopa/levodopa. 85 After 6 months, the mean on time per 18-hour period increased by 1.5 hours in the entacapone-treated group compared with the placebotreated group (p <0.001). Withdrawal of entacapone resulted in a return to baseline on time levels. Mean off time during an 18-hour day decreased by 1.2 hours in the entacapone-treated group compared with the placebo-treated group (p <0.001). Motor scores on the UPDRS decreased by about 10% from baseline in the entacapone-treated group compared with the placebo group (p <0.01). Improvements of approximately 10% to 20% in these motor scores usually produce clinically significant improvements as indicated by increased functional capacity and decreased parkinsonian symptoms (bradykinesia and rigidity). Patients who received entacapone could also lower their levodopa daily dose by an average of 79 mg, whereas placebotreated subjects required an increase of 12 mg in their average daily levodopa dose (p <0.001). A 3-year open-label extension of this trial demonstrated continued efficacy and tolerability of entacapone.
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In the second study, 205 patients were randomly assigned to receive either entacapone 200 mg or placebo (up to 10 doses per day) with each dose of carbidopa/levodopa. 86 At baseline, patients had experienced about 4 years of motor fluctuations and had been taking levodopa for about 9 years. Approximately 80% of the study subjects continued to take other antiparkinsonian therapies, including anticholinergic agents, selegiline, dopamine agonists, and amantadine. Compared with placebo over the course of 8 to 24 weeks, daily, on time increased by about 1 hour (p <0.05) in patients treated with entacapone, with the greatest improvements observed in those who had a smaller percentage of on time at baseline. Those treated with entacapone also had about a 10% reduction in their total UPDRS scores, and they decreased their daily levodopa dose by about 100 mg (13%). Entacapone is approved for use as adjunctive therapy to levodopa for the treatment of PD in patients experiencing wearingoff or end-of-dose deterioration. It is not necessary to titrate the dose; rather, it is given as one 200-mg tablet with each carbidopa/levodopa administration, up to eight tablets per day. It is available in a combination tablet with a 1:4 ratio of immediaterelease carbidopa/levodopa that patients can be switched to once they are stabilized individually on carbidopa/levodopa and entacapone. If dyskinesias occur, it may be necessary to lower the levodopa dose by approximately 10% to 25%, particularly if the patient is receiving more than 800 mg/day of levodopa. Although pramipexole is being discontinued in L.M., he should still be monitored for dyskinesias, especially during the first few weeks of therapy, as it may also be necessary to lower his carbidopa/ levodopa dose.
Early initiation of a COMT inhibitor from the time levodopa is first introduced has been proposed as a way of reducing the occurrence of levodopa-induced motor complications 88 ; theoretically, such a strategy should provide more-stable plasma levels of levodopa and lessen pulsatile stimulation of striatal dopamine receptors normally observed with intermittent levodopa dosing. This strategy was recently tested in the Stalevo Reduction in Dyskinesia Evaluation in Parkinson's Disease (STRIDE-PD) study, a multicenter, double-blind study that randomly assigned 747 patients to initiate either carbidopa/levodopa or carbidopa/levodopa/entacapone four times daily.
88 Surprisingly, patients randomly assigned to receive carbidopa/levodopa/ entacapone actually had a shorter time to onset of dyskinesia (hazard ratio, 1.29; p = 0.04) and increased dyskinesia frequency at week 134 (42% vs. 32%; p = 0.02). These findings may have been confounded by an increased use of dopaminergic therapy in the entacapone group or may reflect relatively unstable plasma levodopa levels given that levodopa was not delivered continuously. The findings of the STRIDE-PD study do not support the early administration of entacapone in combination with levodopa to reduce the occurrence of motor complications.
Adverse Effects
CASE 57-1, QUESTION 18: What are the adverse effects of entacapone, and how should they be managed?
Most entacapone-induced adverse effects are consistent with increased levodopa exposure. They include dyskinesias (50%-60%), nausea (15%-20%), dizziness (10%-25%), and hallucinations (1%-14%). 85, 86 Reducing the levodopa dosage by 10% to 15% as a strategy for circumventing these effects was successful in about one-third of patients experiencing dyskinesias. Other adverse effects related to entacapone include urine discoloration (11%-40%), abdominal pain (6%), and diarrhea (10%). 85, 86 Urine discoloration (brownish-orange) is attributed to entacapone and its metabolites and is considered benign, but patients should be counseled regarding this effect to avoid undue concern. The most common reason for withdrawal from clinical studies and discontinuation of therapy was severe diarrhea (2.5%). No monitoring of liver function tests is required during entacapone therapy.
Recently, the Food and Drug Administration notified health care professionals that it is undertaking a meta-analysis to examine the cardiovascular risks associated with entacapone.
89 This action was prompted by an evaluation of data from the STRIDE-PD study, which indicated that patients taking the combination carbidopa/levodopa/entacapone may be at an increased risk for cardiovascular events (heart attack, stroke, and cardiovascular death) compared with those taking carbidopa/levodopa.
Monoamine Oxidase-B Inhibitors
SELEGILINE AND RASAGILINE
CASE 57-2 QUESTION 1: K.B. is a 61-year-old woman who presents to the movement disorders clinic after referral from her family doctor for a presumptive diagnosis of PD. She is Hoehn
Neurologic Disorders
and Yahr stage 1, with slightly decreased arm swing on the left side and unilateral resting hand tremor. Her past medical history is significant for hypertension and mild renal insufficiency (serum creatinine of 1.4 mg/dL), likely owing to the fact that she was born with only one functioning kidney. Since her initial visit with her family physician, she has been researching information about different PD treatments from several PD-related websites. She is particularly interested today in learning more about possible neuroprotective effects of medications for PD. What role do MAO-B inhibitors have in the treatment of PD, and is there any evidence for neuroprotection?
The development of effective disease-modifying therapies for PD is largely precluded by the inability to readily identify individuals in the presymptomatic state. By the time patients present with clinical symptoms, substantial neuropathology has accumulated during the long preclinical evolution of the disease; an ability to recognize PD at an earlier stage would be a major breakthrough. A number of agents have exhibited neuroprotective effects in animal models, but none have had a clear impact on clinical outcomes in human studies.
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SELEGILINE
Selegiline (also referred to as deprenyl) is an irreversible inhibitor of MAO type B, a major enzymatic pathway responsible for the metabolism of dopamine in the brain. 91 The discovery of MPTP fostered the development of animal models in which it was found that the neurotoxicity associated with MPTP is not directly caused by MPTP itself, but rather the oxidized product, l-methyl-4-phenylpyridinium (MPP). 92 The conversion to MPP is a two-step process mediated in part by MAO-B. Inhibition of MAO-B can inhibit the oxidative conversion of dopamine to potentially reactive peroxides. In animals, pretreatment with selegiline protects against neuronal damage after the administration of MPTP.
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The Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism (DATATOP) study was designed to test the hypothesis that the combined use of selegiline and an antioxidant (α-tocopherol) early in the course of the disease may slow disease progression. 94 The primary outcome was the length of time that patients could be sustained without levodopa therapy (an indication of disease progression). Early treatment with selegiline 10 mg/day delayed the need to start levodopa therapy by approximately 9 months compared with patients given placebo; however, long-term observation showed that the benefits of selegiline were not sustained and diminished with time. During an additional year of observation, patients originally randomly assigned to selegiline tended to reach the end point of disability even more quickly than did those not assigned to receive selegiline. Initial selegiline treatment did not alter the development of levodopa's adverse effects such as dyskinesias and wearing-off and on-off phenomena.
Although selegiline does not appear to have neuroprotective effects in humans, it may have a role as a symptomatic adjunct to levodopa in more advanced disease. Studies have found improvement in the wearing off effect of levodopa in 50% to 70% of patients treated with selegiline and a reduction in as much as 30% in the total daily dose of levodopa. 95, 96 The on-off effect is less responsive to the addition of selegiline.
Selegiline is available in a 5-mg capsule or tablet, and as a 1.25-mg orally disintegrating tablet. It is also available in a transdermal patch, but this formulation is not approved for use in PD (approved for treatment of depression). The bioavailability of conventional selegiline is low, and it undergoes extensive hepatic first-pass metabolism into amphetamine-based metabolites, which have been hypothesized to be neurotoxic. 91 The usual dosage of conventional selegiline is 10 mg/day given in 5-mg doses in the morning and early afternoon. It is not given in the evening because excess stimulation from metabolites (l-methamphetamine and l-amphetamine) can cause insomnia and other psychiatric side effects. 91 The orally disintegrating tablet formulation dissolves in the mouth on contact with saliva and undergoes pregastric absorption. This is an improvement over conventional selegiline because it minimizes the effect of first-pass metabolism and results in higher plasma concentrations of selegiline and reductions in the amphetamine-based metabolites.
97 Indeed, this formulation was shown to reduce off time by 32% (2.2 hours) compared with 9% (0.6 hours) for placebo in a 12-week, randomized, multicenter, parallel group, doubleblind study. 98 Because selegiline selectively binds to MAO-B in usual doses (≤10 mg/day), it does not produce a hypertensive reaction ("cheese effect") with dietary tyramine or other catecholamines. It is still recommended, however, that patients be counseled regarding this potential risk.
RASAGILINE
Rasagiline is a second-generation, propargylamine-type irreversible selective inhibitor of MAO-B. It is indicated as monotherapy in early disease or as adjunct therapy to levodopa in advanced disease. Rasagiline is differentiated from selegiline primarily in that it is a more potent inhibitor of MAO-B, and it is not metabolized into amphetamine-based metabolites.
99 Like selegiline, rasagiline has also been found to protect from MPTP-induced parkinsonism in animal models.
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Rasagiline was studied as monotherapy in early PD in a randomized, double-blind, placebo-controlled trial comparing rasagiline 1 mg (n = 134) or 2 mg (n = 132) daily with placebo (n = 138). After 6 months of therapy, the mean adjusted change in UPDRS scores compared with placebo were -4.2 and -3.56 in the 1-and 2-mg groups, respectively (p <0.001 for both).
101 These changes are quantitatively similar to those observed with levodopa therapy. This study used a delayed-start design, wherein at the end of the initial 6 months of treatment, patients who received placebo were then switched over to receive active treatment with rasagiline, and the rasagiline-treated patients continued on therapy. After an additional 6 months of study, it was found that patients receiving rasagiline for all 12 months had less functional decline than patients in whom rasagiline was delayed.
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The mean adjusted difference at 12 months for patients receiving rasagiline 2 mg/day for all 12 months was -2.29 compared with the delayed-start rasagiline 2-mg group (p = 0.01). These encouraging findings suggested that neuroprotection might be afforded by rasagiline, and prompted a larger, more definitive study.
The Attenuation of Disease Progression with Azilect Given Once-daily (ADIAGO) study was conducted in follow-up to the earlier findings that suggested the possibility of neuroprotection with rasagiline. This was also a randomized, placebo-controlled trial using the delayed-start methodology, but with a much larger sample size (n = 1,176). 103 Patients were randomly assigned to receive rasagiline (either 1 or 2 mg/day) or placebo for 36 weeks. At 36 weeks, rasagiline-treated subjects continued therapy, and the placebo group was switched to either 1 or 2 mg/day of rasagiline; all patients were then followed for an additional 36 weeks. To prove disease modification attributable to rasagiline with either dose, the early-start treatment group had to meet each of three hierarchical end points, based on magnitude and rate of change of UPDRS scores during different periods of the study. At the end of the study, the early-start group receiving rasagiline 1 mg/day met all end points, suggesting a possible disease-modifying effect, but Chapter 57 the 2-mg dose failed to meet all three of the required end points. The inconsistency between doses led the authors to state that they could not definitively conclude that rasagiline 1 mg/day has disease-modifying effects. 103 Rasagiline has also been studied as an adjunct to levodopa in advanced disease. When added to levodopa therapy, rasagiline can improve motor fluctuations, reducing off time by 1.4 hours and 1.8 hours compared with 0.9 hours for placebo (p = 0.02 and p <0.0001 for 0.5-and 1-mg/day groups, respectively).
104 Significant improvements were reported in the UPDRS subscores for ADLs in the off state and motor performance in the on state, as well as clinician global assessments. Dyskinesias were slightly worsened in the 1-mg/day group. As adjunctive therapy to levodopa, rasagiline appears to provide similar benefit to entacapone, and is also given a Level A evidence rating for reducing off time in the Practice Parameter addressing motor fluctuations and dyskinesias. 66 When compared with entacapone 200 mg administered with each levodopa dose, rasagiline 1 mg/day reduced total daily off time in a similar manner (decrease of 21% or 1.18 hours for rasagiline and 21% or 1.2 hours for entacapone).
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Rasagiline is available in 0.5-and 1-mg tablets. When used as monotherapy, it is initiated at 1 mg daily. When combined with levodopa, the initial dose is lowered to 0.5 mg daily, and can be increased to 1 mg daily based on response. Although tyramine-challenge studies have not demonstrated any clinically significant reactions, the product labeling still contains a warning that patients should be advised to restrict tyramine intake. 106, 107 Rasagiline is well-tolerated; headache, dizziness, and nausea appear to be the most common adverse effects when rasagiline is given as monotherapy.
107 Reduction of levodopa dose may be necessary if dyskinesias occur when rasagiline is added in combination to levodopa. Similar precautions regarding drug interactions exist with rasagiline as selegiline; that is, sympathomimetics, meperidine, dextromethorphan, other MAO inhibitors, and selective serotonin reuptake inhibitors (SSRI) should be avoided or used with caution. Because rasagiline is metabolized by CYP1A2, inhibitors such as ciprofloxacin may increase plasma concentrations of rasagiline.
The search for agents capable of clinically apparent neuroprotection remains a primary focus in the management of PD. The disappointing legacy of selegiline and the ambiguity of the ADIAGO study results with rasagiline underscore the fact that overt and tangible neuroprotective effects of PD therapies remain elusive. Nevertheless, given the efficacy of rasagiline in early disease, it would be a reasonable agent to try in a patient such as K.B. who presents very early in her disease course and seeks a possible neuroprotective agent. Depending on her degree of functional impairment caused by the tremor, additional therapy may be necessary. Anticholinergic drugs have been used to treat PD since the mid-1800s, when it was discovered that symptoms were reduced by the belladonna derivative hyoscyamine sulfate (scopolamine). 16 These drugs work by blocking the excitatory neurotransmitter acetylcholine in the striatum, which minimizes the effect of the relative increase in cholinergic sensitivity. Until the late 1960s, when amantadine and levodopa were introduced, anticholinergics were a mainstay of treatment; however, because of their undesirable side effect profile and poor efficacy relative to levodopa in treating bradykinesia and rigidity, anticholinergic agents are no longer used as first-line agents. Instead, they are usually reserved for the treatment of resting tremor early in the disease, particularly in younger patients with preserved cognitive function. Given her history and clinical presentation, K.B. would probably benefit from an anticholinergic drug such as trihexyphenidyl 1 mg/day. K.B. should be observed carefully for adverse effects on initiation of an anticholinergic. These drugs produce both peripherally and centrally mediated adverse effects. Peripheral effects, such as dry mouth, blurred vision, constipation, and urinary retention, are common and bothersome.
Anticholinergics
16 Anticholinergic agents can increase intraocular pressure and should be avoided in patients with angle-closure glaucoma. Central nervous system effects can include confusion, impairment of recent memory, hallucinations, and delusions. 16 Patients with PD are more susceptible to these central effects because of advanced age, intercurrent illnesses, and impaired cognition. 16 As K.B.'s disease eventually progresses and she develops other nonmotor complications, the benefit versus risk of anticholinergic therapy should be periodically re-evaluated.
Investigational Pharmacotherapy
CASE 57-2, QUESTION 3: Are there any antioxidants, dietary supplements, or other investigational therapies that may benefit K.B.? ANTIOXIDANTS Antioxidants have been hypothesized to benefit patients with PD through their ability to act as free radical scavengers. The most comprehensive evaluation of antioxidant therapy for PD comes again from the DATATOP study. 95, 108, 109 In this study, patients were assigned to one of four treatment regimens: α-tocopherol (2,000 international units/day) and selegiline placebo; selegiline 10 mg/day and α-tocopherol placebo; selegiline and α-tocopherol active treatments; or dual placebos. The primary end point was time to requirement of levodopa therapy. After approximately 14 months of follow-up, no difference was seen between the α-tocopherol group and placebo group in time to require levodopa. 109 Thus, despite the theoretic benefit, clinical data are lacking to support the routine use of α-tocopherol, and it would not be recommended in K.B.
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COENZYME Q10
Coenzyme Q10 (CoQ 10 ) is an antioxidant involved in the mitochondrial electron transport chain, and has been shown to have reduced levels in patients with PD. 110 The finding that MPTP can induce parkinsonism through inhibition of complex I in the mitochondrial electron transport chain led to the hypothesis that supplementation with CoQ 10 may help restore dysfunctional mitochondria.
111 Early results in a trial of 80 patients with untreated PD, randomly assigned to placebo or CoQ 10 at dosages of 300, 600, or 1,200 mg/day in four divided doses, were promising.
112 Subjects were followed for up to 16 months or until therapy with levodopa was required. The primary outcome was a change in total score on the UPDRS from baseline to the last visit. Total UPDRS scores increased (indicating worsening of symptoms) to a greater extent in placebo-treated patients than in those treated with CoQ 10 (+11.99 for placebo, +8.81 for 300 mg/day, +10.82 for 600 mg/day, and +6.69 for 1,200 mg/day).
A larger study was undertaken in follow-up, using a futility design, randomly assigning 213 untreated PD patients to CoQ 10 600 mg four times daily or placebo. 113 The primary outcome Neurologic Disorders measure was the mean change in total UPDRS score from baseline to either the time required for symptomatic therapy or 12 months, whichever came first. The threshold value for futility of CoQ 10 was defined as 30% less progression on the total UPDRS than the 10.65-unit change observed historically in the placebo arm of the DATATOP trial, or 7.46. After 12 months of therapy, the mean change in the CoQ 10 group was 7.52 compared with 6.31 in the placebo group. Based on the prespecified criteria, although CoQ 10 did not meet the prespecified end point of a change of 7.46 or less, it could not be rejected as futile and met criteria for further clinical testing. Further testing of CoQ 10 in phase 3 trials is currently being conducted. In the meantime, given the small likelihood of harm from CoQ 10 , K.B. can be counseled about the possibility for modest benefits and advised to make an informed decision about using it.
CREATINE AND MINOCYCLINE
Similar to the theory for efficacy of CoQ 10 , creatine plays a role in mitochondrial energy production and has been shown to protect from MPTP-induced dopamine depletion in animal models. 114 Minocycline is an anti-infective agent that also displays anti-inflammatory effects, and is hypothesized to alter the neuroinflammatory response that occurs as dopaminergic neurons are lost in PD. Minocycline has been shown to be protective in MPTP animal models of PD.
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The use of both creatine and minocycline in PD was examined in a futility-design study, in which 200 patients with early PD not requiring therapy were randomly assigned to receive creatine (n = 67) 10 g/day, minocycline 200 mg/day (n = 66), or placebo (n = 67). 116 The study was identically designed to the CoQ 10 study discussed previously and used the same primary end points. After 12 months, the mean change in the total UPDRS was 5.6 units in the creatine group, 7.09 in the minocycline group, and 8.39 in the placebo group. Based on the prespecified criteria, neither creatine nor minocycline could be rejected as futile and met criteria for further clinical testing. Additional studies of these agents are currently ongoing. Given the unresolved issues surrounding the induction of antibiotic resistance with long-term use of an agent such as minocycline, it should be avoided in K.B. Likewise, given her mild renal insufficiency, she should also be advised to avoid creatine.
Surgical Therapies for PD
CASE 57-3 QUESTION 1: S.L. is a 68-year-old man with a 10-year history of PD, now considered to be in Hoehn and Yahr late stage 3. His current regimen includes sustained-release carbidopa/levodopa 50/200 mg twice daily, immediate-release carbidopa/levodopa 25/100 mg TID, ropinirole 2 mg TID, and amantadine 100 mg twice daily. S.L.'s overall control of his PD has diminished greatly in the last couple of months. His on time averages around 6 hours/day, with the majority of it accompanied by troublesome dyskinesias. Most days he needs some assistance with ADLs. His cognitive function remains well preserved, and he is not depressed. He has heard about surgical procedures that might benefit patients with PD. Is surgical therapy superior to medical therapy in patients with advanced PD?
Two types of surgical therapies have been used in patients with advanced PD who cannot be adequately controlled with medications. The first involves making an irreversible surgical lesion in a specific location in the brain (e.g., posteroventral pallidotomy or stereotaxic thalamotomy); the second involves surgical implan- tation of a device that sends electrical impulses to specific parts of the brain (e.g., deep brain stimulation [DBS]) (Fig. 57-5 ). Posteroventral pallidotomy has been shown to reduce dyskinesias on the contralateral side and may permit the use of higher dosages of levodopa for managing rigidity and bradykinesia. 117 However, a significant disadvantage is the need to make a lesion near the optic tract, which may risk visual loss. Other possible risks of pallidotomy include weakness, paralysis, and hemorrhage that can cause stroke and speech difficulty. Stereotaxic thalamotomy has been shown to reduce symptoms of debilitating tremor and improve rigidity in patients with PD.
118 This intervention has eliminated contralateral tremor in 80% of patients, and improvement has been sustained for up to 10 years. However, as with pallidotomy, a disadvantage of thalamotomy is the need to make an irreversible lesion in the basal ganglia that may limit the effectiveness of newer procedures as they become available. Thus, DBS is now the preferred surgical method for treating advanced PD that cannot be adequately controlled with medications. DBS uses an implanted electrode in the brain, in either the subthalamic nucleus (STN) or the globus pallidus interna (GPi), that is connected to a subcutaneously implanted pacemaker. This permits delivery of a high-frequency stimulation to the desired target. Advantages of DBS include no need for an irreversible brain lesion, and it provides flexibility for altering the target site and program stimulation parameters.
The efficacy of DBS in advanced PD was shown in a two-part study of 255 patients with idiopathic PD responsive to levodopa but with persistent and disabling motor symptoms. 119 Patients were randomly assigned to DBS (further randomly assigned to either STN or GPi targets) or best medical therapy (management by movement disorders specialists) and followed for 6 months for the primary outcome of time spent in the on state without troubling dyskinesias. Patients receiving DBS gained a mean of 4.6 hours/day of on time without troubling dyskinesias compared with 0 hours/day for best medical therapy Chapter 57 (p <0.001). Additionally, 71% of patients receiving DBS experienced clinically meaningful motor function improvements (≥5-point change in UPDRS motor score) compared with only 32% of patients receiving best medical therapy (p <0.001).
119 At the end of the 6 month assessment, all patients (including those originally randomly assigned to best medical care) proceeded to DBS with random assignment to STN or GPi targets, and outcomes were evaluated at 24 months. 120 There were no significant differences in the change in UPDRS motor score between those receiving DBP targeting the STN and those with the GPi targeted (p = 0.05). However, secondary outcomes revealed some minor between-group differences; those undergoing DBS targeting the STN required lower doses of dopaminergic agents (p = 0.02), and those receiving DBS targeting the GPi had less decline in visuomotor processing speed (p = 0.03), greater improvement in depression (p = 0.02), and fewer adverse events (51% vs. 56%; p = 0.35).
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CASE 57-3, QUESTION 2: What surgical therapy would be most appropriate for S.L.?
S.L. appears to be an ideal candidate for DBS. Candidates for DBS should have idiopathic PD and be levodopa-responsive, but continue to experience motor complications or tremor despite optimal pharmacotherapeutic regimens. Ideally, DBS should be avoided in patients with pre-existing cognitive or psychiatric problems owing to a slight risk of decline in cognition. No strict age limitation for DBS exists, but patients younger than 70 years of age, such as S.L., appear to recover from surgery more quickly and show greater motor improvements. Although both the GPi and STN would be acceptable targets of therapy in S.L., nonmotor factors may be considered when selecting the surgical target for DBS. DBS of the STN consistently demonstrates marked reduction in the need for escalating levodopa dosages compared with DBS of the GPi, 120-123 but the results of the most recent comparative trial suggest other nonmotor symptoms may be affected more favorably when targeting the GPi. In one longitudinal study of patients with PD, the most common nonmotor symptoms were psychiatric symptoms (68%, most commonly anxiety), fatigue (58%), leg pain (38%), insomnia (37%), urinary symptoms (35%), drooling (31%), and difficulty concentrating (31%). 125 The management of several commonly encountered nonmotor symptoms are reviewed below. The prevalence of dementia in patients with PD increases with age and duration of disease and is approximately 6-to 12-fold greater than in age-matched control subjects.
16 One longitudinal study of 136 incident cases of PD followed for 20 years found that nearly 100% eventually exhibited dementia.
127 Successful management of cognitive impairment in patients with PD first requires that all potentially reversible causes and underlying contributing factors be addressed. These include treating infections, dehydration, and metabolic abnormalities, as well as eliminating unnecessary medications (particularly anticholinergics, sedatives, anxiolytics) that can exacerbate dementia or delirium.
Experience with cholinesterase inhibitors such as donepezil and rivastigmine for treating cognitive impairment in PD indicates marginal improvements with their use. [128] [129] [130] Outcomes of these studies are measured using a variety of scales, such as the Mini Mental Status Examination, the Alzheimer's Disease Assessment Scale-Cognitive Subscale, the Alzheimer's Disease Assessment Scale-Clinician's Global Impression of Change, and the Clinician's Interview-Based Impression of Change Plus Caregiver Input. Compared with placebo, the cholinesterase inhibitors often result in a statistically significant change of a couple of points in these scales. It is unclear, however, to what extent the changes in the scores of these outcome measures are clinically relevant in such areas as ability to perform ADLs without assistance and delay in nursing home placement.
Although the American Academy of Neurology Practice Parameter addressing depression, psychosis, and dementia in PD suggests that either donepezil or rivastigmine can be considered for patients such as J.D., 18 he must be monitored closely for signs of deterioration of motor function such as worsening of tremor. Cholinesterase inhibitors are associated with other adverse events that may be overlooked and attributed to the PD itself, including sialorrhea, excessive lacrimation, incontinence, nausea, vomiting, and orthostasis. Perhaps more important than any medication therapy, adequate social support for J.D. should be ensured. As he becomes further dependent on family members for assistance with ADLs, the increased needs of the caregiver(s) should also be considered. In J.D.'s case, attending adult day-care several times weekly, if available, would provide a structured, supervised environment for interaction with others, as well as providing a rest period for his caregiver. Dementia is a leading cause of nursing home placement for patients with PD. Despite being one of the strongest predictors of quality of life in PD patients, depression is often poorly recognized and inadequately treated. 131, 132 This is likely because of the fact that depression and PD share overlapping features that often confound the identification of depression. Such features may include withdrawal, lack of motivation, flattened affect, decreased physical activity, or bradyphrenia.
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Treatment of depression in PD should first focus on providing adequate treatment of the symptoms of PD by attempting to restore mobility and independence, particularly in patients whose depression can be attributed to lengthy off periods. Antiparkinson drugs, such as pramipexole, can be associated with mood-enhancing effects independent of their ability to reduce time in the off state. 133, 134 Small trials and case reports have shown that depression in patients with PD can be successfully treated with antidepressant drugs, including tricyclic agents such as amitriptyline, desipramine, nortriptyline, bupropion, and SSRIs such as citalopram and paroxetine. 18, 135, 136 Given the overall lack of controlled trials, it is difficult to know whether expected benefits reflect class responses or are unique to the individual agents studied. Importantly, the potential for adverse effects should always be considered when selecting an antidepressant in PD. For example, some SSRIs, such as fluoxetine, can be activating. Although this may be beneficial in patients who are apathetic or withdrawn, it may worsen symptoms in patients with PD who are agitated. 16, 137 With tricyclic antidepressants, care must be taken to observe for anticholinergic side effects that may worsen PD symptoms, such as impaired cognition, delayed gastric emptying (which may reduce levodopa effectiveness by increasing levodopa degradation in the gut), urinary problems, orthostatic hypotension, and increased risk of falls. Electroconvulsive therapy may be considered in refractory cases, but may adversely affect cognition.
Based on J.D.'s symptoms, it is reasonable to start him on an antidepressant. Clinical experience suggests a good initial choice for balancing efficacy and safety is probably an SSRI, such as citalopram. As with other patients with depression, the choice of agent should be individualized based on other pragmatic factors such as cost, potential for adverse effects, and personal or family history of response to prior agents. Regardless of which agent or class of antidepressant is selected, therapy should be started at the lowest dose and gradually titrated to effect. He should be monitored closely for side effects, particularly anticholinergic symptoms with tricyclic antidepressants, and for any adverse effects on mobility. He should be observed carefully for changes in parkinsonian symptoms, including development of extrapyramidal symptoms, as well as any signs of psychomotor agitation. Short-term use of benzodiazepines, such as lorazepam or alprazolam, may also provide relief of anxiety symptoms, 124 but must be used cautiously owing to adverse effects on cognition and risk of falling. Generally, anxiety symptoms should improve with treatment of the underlying depression.
PSYCHOSIS
The incidence of psychotic symptoms increases with age and cognitive impairment in patients with PD. Other risk factors include higher age at PD onset, high doses of dopaminergic drugs, and REM sleep behavior disorder.
138 Symptoms are often more pronounced at night (the "sundowning" effect), and hallucinations are typically visual. As with the management of cognitive impairment, it is important to eliminate or minimize any potential causative factors, particularly anticholinergic medications that could be contributing to the hallucinations or delirium. In some patients, reducing the dose of levodopa improves mental function and also provides satisfactory control of motor features. If it is not possible to achieve a balance between preserving motor control Chapter 57
and decreasing neuropsychiatric symptoms through reduction in levodopa dosage, antipsychotics may be considered.
Older antipsychotic medications, such as haloperidol, perphenazine, and chlorpromazine, block striatal dopamine D 2 receptors and may exacerbate parkinsonian symptoms. Therefore, these agents are not recommended. 16 Newer atypical antipsychotics are more selective for limbic and cortical D 3 , D 4 , D 5 receptors; they have minimal activity at D 2 receptors and may control symptoms without worsening parkinsonism. Of these agents, clozapine has the best evidence of efficacy in patients with PD without adversely affecting motor function, and should be preferentially considered. 18, 139 However, its use is complicated by the need for frequent monitoring of white blood cell counts because of the risk of agranulocytosis. Other newer agents, particularly quetiapine, appear promising and have controlled psychosis without worsening parkinsonism. 140, 141 Risperidone and olanzapine have also been studied, but both worsened parkinsonism and were inferior to clozapine in patients with PD. 142, 143 Aripiprazole, also a newer atypical antipsychotic, has been associated with worsening motor function in patients with PD, whereas experience with ziprasidone has yielded mixed results.
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AUTONOMIC DYSFUNCTION
Patients with PD frequently experience dysautonomia, including orthostasis, erectile dysfunction, constipation, nocturia, sensory disturbances, dysphagia, seborrhea, and thermoregulatory imbalances. Management of these symptoms is generally supportive, and appropriate medical interventions similar to those used in other geriatric patients can be used to treat these symptoms whenever encountered. In some cases, fludrocortisone or midodrine can be considered if orthostatic hypotension is severe, although they have been subject to little study in PD patients specifically.
124 Other possibly effective treatments for symptoms of autonomic dysfunction outlined in the American Academy of Neurology Practice Parameter include sildenafil for erectile dysfunction and polyethylene glycol for constipation.
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FALLS
Patients with PD and their caregivers should be counseled on the prevention of falls because they can result in serious morbidity and mortality. Falls generally result from one of several factors, including postural instability, freezing and festination, levodopainduced dyskinesia, symptomatic orthostatic hypotension, coexisting neurologic or other medical disorders, and environmental factors. 16 Prevention remains the best strategy and includes environmental precautions, such as proper lighting, use of handrails, removing tripping hazards, and incorporating physical and occupational therapy. Reversible causes of postural or gait instability should be addressed whenever suspected.
SLEEP DISORDERS
Parasomnias often experienced by elderly persons are accentuated in PD patients. 16 Insomnia, sleep fragmentation owing to PD symptoms, restless leg syndrome, and REM sleep disorder (characterized by vivid dreams that are often acted out, especially if frightening) are common and a source of decreased quality of life. When sleep dysfunction can be directly attributed to PD symptoms, such as akinesia, tremor, dyskinesia, or nightmares, dosage adjustment of dopaminergic medications is indicated. Proper sleep hygiene should be encouraged. Short-acting benzodiazepines can be used if insomnia occurs; however, a longeracting agent or controlled-release formulation may be preferred if the patient wakes early and is unable to return to sleep. If excessive daytime drowsiness occurs, modafinil may be considered.
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Similar to dysautonomia, management of sleep disorders that are not directly attributable to PD symptoms can be managed supportively, as in other geriatric patients. 
RESTLESS LEG SYNDROME AND PERIODIC LIMB MOVEMENTS OF SLEEP Clinical Presentation
CASE 57-5 QUESTION 1: J.J., a 47-year-old woman, presents to her family physician complaining of daytime fatigue and difficulty sleeping at night because of "jumpy legs." She reports being able to sleep only 4 to 5 hours per night because of the leg restlessness, and feels unrefreshed after sleep. On further questioning, she describes the sensation in her legs as being like "bugs crawling under the skin." The sensation is not painful. She explains that the symptoms worsen in the evening and at night and are partially relieved with walking. She recalls that her mother had similar symptoms. J.J.'s spouse notes that she often "kicks" him in her sleep. Review of her medical history shows an otherwise healthy postmenopausal woman. What signs and symptoms are suggestive of restless legs syndrome (RLS) in J.J.? What laboratory tests or diagnostic procedures should be performed in J.J. to evaluate her condition?
Restless legs syndrome, also known as Ekbom disease, is a disabling sensorimotor disorder estimated to affect approximately 2% of the adult population.
145 Although most patients with mild symptoms will not require treatment, RLS can be associated with adverse health outcomes, including sleep-onset insomnia, missed or late work, anxiety, depression, marital discord, and even suicide in severe cases.
Four essential criteria have been established by the International Restless Legs Syndrome Study Group to diagnose RLS (Table 57-7) . 146 The pathognomonic trait of RLS is an almost irresistible urge to move the legs (akathisia), often associated 
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Neurologic Disorders with uncomfortable paresthesias or dysesthesias felt deep inside the limbs. Patients describe the sensation as "creepy-crawly" or "like soda water in the veins." 147 The symptoms may occur unilaterally or bilaterally, affecting the ankle, knee, or entire lower limb. With progressive disease, symptoms can begin earlier in the day, and progressive involvement of the arms or trunk may occur. Temporary or partial relief of symptoms can be achieved with movement. If patients attempt to ignore the urge to move the legs, akathisia will progressively intensify until they either move their legs or the legs jerk involuntarily.
147 Symptoms usually manifest in a circadian pattern with onset or worsening during nighttime hours (usually between 6 pm and 4 am, with peak symptoms between midnight and 4 am). The circadian pattern persists even in patients with inverted sleep-wake cycles. As a result of their symptoms, patients with RLS become "nightwalkers," spending significant time walking, stretching, or bending the legs in an effort to relieve symptoms.
J.J.'s case is an example of a classic presentation of RLS. The prevalence of RLS increases with age and appears to be slightly more common in women.
148 She describes "creepy-crawly" sensations that are relieved partially with walking, a core feature of RLS. Her symptoms are worse during the evening hours. J.J. reports her mother suffered from similar symptoms. The observation of a familial tendency suggests a genetic component, and several chromosomal loci have been linked to the disease.
149
A strong family history of RLS appears to correlate with an early age of onset (<45 years), whereas presentation at a later age is associated with more neuropathy and accelerated disease progression.
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Most cases of RLS are considered primary or idiopathic; therefore, the diagnosis does not require elaborate laboratory tests or diagnostic procedures. Several conditions are associated with RLS, and include iron deficiency, pregnancy, and end-stage renal disease. A thorough medical history should be taken in J.J. to rule out reversible causes of RLS or other conditions with similar characteristics. Several medications and substances are known aggravators of RLS, including medications with antidopaminergic properties, such as metoclopramide and prochlorperazine. Nicotine, caffeine, and alcohol can aggravate RLS through their own ability to interfere with quality of sleep. Additionally, SSRIs, tricyclic antidepressants, and commonly used over-the-counter antihistamines, such as diphenhydramine, can trigger or worsen RLS symptoms. 149 Hypotensive akathisia, leg cramps, and other conditions such as arthritis, which can cause positional discomfort with extended periods of sitting in one position, can mimic RLS. These conditions are easily distinguished from RLS because they are usually localized to certain joints or muscles, do not have a circadian pattern, and are not associated with an uncontrollable urge to move.
With an otherwise unremarkable physical examination and medical history, specific laboratory tests that should be performed in J.J. are limited to serum ferritin and percent transferrin saturation (total iron-binding capacity) to rule out iron deficiency anemia. It is important to note that ferritin is an acute-phase reactant and may be artificially elevated if there is an underlying inflammatory or infectious condition. Therefore, the ferritin level should always be accompanied by the percent transferrin saturation. Several studies have documented a relationship between low ferritin concentrations and increased symptom severity.
150,151 J.J. is postmenopausal, so a pregnancy test is not necessary. Polysomnography is not usually indicated unless there is clinical suspicion for sleep apnea or if sleep remains disrupted despite treatment of RLS. When clinical suspicion from the physical examination or medical history suggests a possible peripheral nerve or radiculopathy cause, a routine neurologic panel, including thyroid function tests, fasting glucose, vitamins B 6 and B 12 , and folate, should be obtained. 149 Renal function tests (serum creatinine and blood urea nitrogen) can be obtained to screen for uremia, although RLS does not usually occur in this situation until the patient has reached end-stage renal failure. In addition to the presence of RLS, J.J.'s spouse has noticed what are likely PLMS. PLMS, also known as nocturnal myoclonus, are best described as involuntary clonic-type movements of the lower extremities while sleeping that usually involve bilateral ankle dorsiflexion, knee flexion and hip flexion. Approximately 80% of patients with RLS will also have PLMS, but PLMS can occur by itself and is also associated with significant sleep dysfunction. The diagnosis of PLMS usually requires a polysomnogram; the universally accepted criteria for diagnosis are that there should be at least four periodic leg movements (PLMs) in a 90-second period, with contractions typically lasting 0.5 to 5 seconds and recurring every 5 to 90 seconds. 152 A PLM index (PLMI) is calculated by dividing the total number of PLMs by sleep time in hours; an index of more than 5 but less than 25 is considered mild, a PMLI of more than 25 and less than 50 is moderate, and a PLMI of more than 50 is severe. The diagnosis of PLM disorder can be made when patients present with insomnia, tiredness, and daytime sleepiness in the presence of a high PLMI. 153 There is considerable overlap in the treatments of PLMS and RLS. Because J.J. clearly has RLS there is no need to perform a polysomnogram. The diagnosis of PLMS in her case is incidental and would not alter the clinical management. An exception to this would be if J.J.'s medical history revealed the possibility of sleep apnea, as there is a high association between PLMS and upper airway resistance 154 ; a polysomnogram would then be indicated.
Treatment
CASE 57-5, QUESTION 3: The decision is made to treat J.J.'s symptoms with medication. What pharmacologic therapy should be selected? What nonpharmacologic therapies should be recommended?
Figure 57-6 presents an approach to the treatment of RLS. Iron supplements can potentially cure RLS symptoms in patients found to be iron deficient. 155 If J.J. is iron deficient, she should be prescribed 50 to 65 mg of elemental iron one to three times daily on an empty stomach with 200 mg of vitamin C to enhance absorption. After ruling out possible reversible causes of RLS, it is important to establish the frequency of J.J.'s symptoms and whether or not they are associated with pain. This information will help determine appropriate therapy.
Several classes of medications are effective for treating RLS.
156
Dopaminergic therapies are most consistently effective in relieving RLS symptoms, improving sleep, and reducing leg movements. The available dopaminergic therapies that have been evaluated in RLS include carbidopa/levodopa, pramipexole, ropinirole, bromocriptine, and rotigotine (not currently available in the United States). 156,157 Dopamine agonists are now the preferred dopaminergic class to treat RLS because they are longer acting than levodopa, which allows for more sustained efficacy and control of symptoms throughout the entire night. J.J. should be started on either ropinirole (0.25 mg initially, up to 0.5-8.0 mg/ day) or pramipexole (0.125 mg initially, up to 0.5-1.5 mg/day), as both are both Food and Drug Administration-approved for treating RLS. Several randomized, controlled clinical trials have
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Bothersome leg symptoms at night documented efficacy of these agents in both objective and subjective ratings of improvement by patients and clinicians with either short-or long-term use. [158] [159] [160] [161] [162] Ropinirole and pramipexole do not appear to differ with regard to efficacy or adverse effects. When used for RLS, ropinirole and pramipexole should be administered 2 hours before bedtime. Adverse effects are similar to those seen with the use of these agents in PD, and patients should be counseled accordingly.
Other medications may also provide modest benefit in RLS, including benzodiazepines, opiates, anticonvulsants, and clonidine.
156 With the exception of gabapentin or opiates, 163, 164 which could be considered initially if J.J.'s discomfort was primarily caused by pain, all are considered to be alternatives to the dopaminergics. The dosing and adverse effects of the benzodiazepines used in RLS are similar to their use in the general population. No evidence suggests that one benzodiazepine is more effective than another for RLS, and selection should be based on the patient's primary sleep disorder complaint. For example, a newer short-acting benzodiazepine with quick onset of action may be preferred in a patient whose primary problem is getting to sleep. Older anticonvulsants such as carbamazepine and valproic acid may be efficacious, but lack substantial study in RLS patients. 156 Newer agents such as pregabalin and topiramate have also been studied with favorable preliminary results. 156, 165 In addition to a dopamine agonist, nonpharmacologic therapies and behavioral techniques should also be recommended for J.J. Most important among these include discontinuing all RLS aggravators and practicing good sleep hygiene. Physical and mental activity (e.g., reading, playing card games, or working on the computer) if patients are unable to sleep can reduce symptoms.
149
Counter stimuli such as massage or hot baths may be helpful.
CASE 57-5, QUESTION 4: After carefully considering the costs of therapy, J.J. and her physician choose levodopa to treat her RLS. She initially responds well to the therapy. One year later, J.J. returns for follow-up. Her dose of carbidopa/levodopa has progressively increased to three 25/100 mg tablets at bedtime. She describes continued worsening of her symptoms, and they do not seem to be relieved with increasing doses of carbidopa/levodopa. Her symptoms are now starting earlier in the evening, occur almost every night, and are now painful. How should J.J.'s therapy be further adjusted?
J.J. is likely experiencing augmentation, a common problem with long-term use of dopaminergic drugs, particularly levodopa. 166 Augmentation is described as a progressive worsening of RLS symptoms after an initial improvement, and is manifested by gradually intensified symptoms that occur earlier in the evening and spread to other parts of the body. 167 It is the most common side effect occurring with long-term use (>3 months) of dopaminergic agents, and usually occurs 6 to 18 months after therapy is initiated.
149 Doses of dopaminergic agents are often increased in response; however, with each incremental dose increase symptoms progress more rapidly until they may occur continuously throughout the day.
149 Although augmentation has been clinically recognized for many years, it has not been systematically studied. The exact etiology is uncertain, but it likely relates to the finding that RLS, unlike PD, is actually a hyperdopaminergic condition with an apparent postsynaptic desensitization that overcompensates during the circadian low point of dopaminergic activity in the evening and night. Adding dopamine in the evening initially corrects the symptoms, but ultimately leads to increasing postsynaptic desensitization.
The highest risk for augmentation is with levodopa. An estimated 50% to 85% of patients on levodopa will develop augmentation, compared with only 20% to 30% with dopamine agonists. 156 The primary treatment strategy in dealing with augmentation is to withdraw the dopaminergic agent and substitute other nondopaminergic agents. Given her presentation, J.J. should have her carbidopa/levodopa discontinued. She should be counseled that her symptoms will likely rebound severely for 48 to 72 hours, but approximately 4 to 7 days later her symptoms should gradually return to baseline or pretreatment state.
With the discontinuation of carbidopa/levodopa in J.J., an alternative therapy should be selected. The selection of an alternative agent in cases in which the initial therapy failed or augmentation occurs must be approached on an individual basis. Although a number of agents are available to choose from, clinical experience generally guides the decision as lack of comparative trials precludes development of any formal recommendations. Because J.J. describes increasing pain with her RLS, it would be appropriate to initiate a trial of gabapentin. If gabapentin is ineffective or not tolerated, J.J. could be prescribed an opiate, which is also an acceptable choice in patients with RLS who have neuropathy or painful dysesthesias. Hydrocodone, oxycodone, methadone, codeine, and tramadol have all demonstrated efficacy in RLS. 149 Augmentation does not prevent a future reintroduction of dopaminergic therapy; in J.J.'s case, a dopamine agonist could be added after an extended dopaminergic-free period if her symptoms are not completely controlled on gabapentin.
ESSENTIAL TREMOR Clinical Presentation
CASE 57-6 QUESTION 1: K.H. is a 52-year-old white female office manager who was referred to a neurologist for evaluation of bilateral tremor. She is otherwise healthy and reports not taking any regularly prescribed medications. She describes her tremor as being present mainly when she performs voluntary movements. The tremor is not noticeable during rest. She also notices the tremor seems to disappear in the evening after drinking a couple of glasses of wine. The tremor interferes with several of her ADLs, including writing, eating, drinking from a cup, and inserting her keys into the ignition. She reports mild interference with her job function and some social embarrassment. No bradykinesia or rigidity is elicited on physical examination. A handwriting sample reveals large characters that are difficult to decipher. Family history reveals that her maternal grandmother and mother both had similar symptoms. What signs and symptoms are consistent with essential tremor in K.H.?
Beginning in the mid-20th century, the term essential tremor (ET) has been consistently used to describe a kinetic tremor for which no definite cause has been established. ET is a common neurologic disorder with an estimated incidence of 616 cases per 100,000 person-years, and a prevalence of about 0.9% to 4.6%. 168, 169 Despite its commonness, it is underrecognized and undertreated, likely because it has been traditionally viewed as a monosymptomatic disorder of little consequence; more recently, it is recognized to be complex and progressive, resulting in significant disability in ADLs and job performance, and social embarrassment. 170 Both the incidence and prevalence of ET increase with age. In addition, ethnicity and family history of ET are consistently identified risk factors; it is approximately five times more common in whites than blacks, and approximately 50% of patients report a positive family history. The latter finding suggests that genetic predisposition may play a role in ET; however, differences in intrafamilial onset and severity suggest environmental factors may also influence underlying susceptibility to the disease. Several environmental toxins have been proposed as causes of ET, including β-carboline alkaloids (e.g., harmane and harmine) and lead, both of which have been found in elevated concentrations in patients with ET compared with normal control subjects. 171, 172 Because parkinsonian tremor and ET are the most common forms of tremor observed in practice, it is important to distinguish between the two because the treatments differ substantially. Diagnostic criteria for ET developed by the Movement Disorder Society are summarized in Table 57 -8. 173 Tremor should first be identified as either an action or resting tremor. Action tremors include kinetic, postural, and isometric tremors. The defining feature of ET is a bilateral, largely symmetrical, 5-to 10-Hz kinetic and postural tremor of the arms. The tremor can also affect head or voice. Kinetic tremor can be elicited in patients during voluntary movement, such as finger-to-nose test, signing their name, drawing spirals, or drinking water from a cup. Postural tremor occurs during sustained arm extension. Although both types of action tremors (kinetic or postural) can be present in ET and PD, areas. 175 Injections in the wrist can cause hand weakness, and dysphagia, hoarseness, and breathiness can occur with injections into the neck or vocal cords. The use of botulinum toxin injections in the United States is also limited by cost. Treatment should occur with the lowest dose, and the interval should be as long as possible between injections. DBS of the ventral intermediate nucleus of the thalamus or unilateral thalamotomy is highly efficacious in reducing ET. 176 Greater improvement in self-reported measures of function and fewer adverse events make DBS the preferred surgical option of the two. 176, 182 Because K.H. is otherwise healthy, she is a good candidate for propranolol therapy. Propranolol can be initiated as needed or on a scheduled basis depending on the degree of impairment and desire of the patient. If the decision is made with K.H. to use propranolol on an as-needed basis, she should begin with one-half of a 20-mg tablet administered 30 minutes to 1 hour before the desired effect. The dose can be increased from onehalf to two tablets. An example of a situation in which this may occur is if she wants to avoid embarrassment with attending a social activity or before certain tasks requiring manual dexterity at work. Given the degree of her impairment, she is probably a better candidate for chronic suppressive therapy with propranolol. In this situation, she can be prescribed 10 mg twice daily and titrated every few days up to 120 to 360 mg/day in divided doses.
